improv
care
adult
patient
communityacquir
pneumonia
cap
focu
mani
differ
organ
sever
develop
guidelin
manag
cap
two
wide
referenc
infecti
diseas
societi
america
idsa
american
thorac
societi
at
respons
confus
regard
differ
respect
guidelin
idsa
at
conven
joint
committe
develop
unifi
cap
guidelin
document
guidelin
intend
primarili
use
emerg
medicin
physician
hospitalist
primari
care
practition
howev
extens
literatur
evalu
suggest
also
appropri
start
point
consult
specialist
substanti
overlap
exist
among
patient
guidelin
address
discuss
recent
publish
guidelin
health
careassoci
pneumonia
hcap
pneumonia
nonambulatori
resid
nurs
home
longterm
care
facil
epidemiolog
mirror
hospitalacquir
pneumonia
treat
accord
hcap
guidelin
howev
certain
patient
whose
condit
includ
design
hcap
better
serv
manag
accord
cap
guidelin
concern
specif
pathogen
implement
guidelin
recommend
local
adapt
guidelin
implement
improv
process
care
variabl
relev
clinic
outcom
strong
recommend
level
evid
enthusiasm
develop
guidelin
deriv
larg
part
evid
previou
cap
guidelin
led
improv
clinic
relev
outcom
consist
benefici
effect
clinic
relev
paramet
list
tabl
follow
introduct
comprehens
protocol
includ
combin
compon
tabl
increas
complianc
publish
guidelin
first
recommend
therefor
cap
manag
guidelin
local
adapt
implement
cap
guidelin
address
comprehens
set
element
process
care
rather
singl
element
isol
strong
recommend
level
iii
evid
develop
local
cap
guidelin
direct
toward
improv
specif
clinic
relev
outcom
moder
recommend
level
iii
evid
almost
major
decis
regard
manag
cap
includ
diagnost
treatment
issu
revolv
around
initi
assess
sever
siteofcar
decis
eg
hospit
vs
outpati
intens
care
unit
icu
vs
gener
ward
import
area
improv
cap
manag
severityofil
score
criteria
confus
uremia
respiratori
rate
low
blood
pressur
age
year
greater
prognost
model
pneumonia
sever
index
psi
use
identifi
patient
cap
may
candid
outpati
treatment
strong
recommend
level
evid
object
criteria
score
alway
supplement
physician
determin
subject
factor
includ
abil
safe
reliabl
take
oral
medic
avail
outpati
support
resourc
strong
recommend
level
ii
evid
patient
score
moreintens
hospit
appropri
avail
intens
inhom
health
care
usual
warrant
moder
recommend
level
iii
evid
physician
often
admit
patient
hospit
could
well
manag
outpati
would
gener
prefer
treat
outpati
object
score
score
psi
assist
identifi
patient
may
appropri
outpati
care
use
score
must
temper
physician
determin
addit
critic
factor
includ
abil
safe
reliabl
take
oral
medic
avail
outpati
support
resourc
direct
admiss
icu
requir
patient
septic
shock
requir
vasopressor
acut
respiratori
failur
requir
intub
mechan
ventil
strong
recommend
level
ii
evid
direct
admiss
icu
highlevel
monitor
unit
recommend
patient
minor
criteria
sever
cap
list
tabl
moder
recommend
level
ii
evid
studi
signific
percentag
patient
cap
transfer
icu
first
h
hospit
mortal
morbid
among
patient
appear
greater
among
patient
admit
directli
icu
convers
icu
resourc
often
overstretch
mani
institut
admiss
patient
cap
would
directli
benefit
icu
care
also
problemat
unfortun
none
publish
criteria
sever
cap
adequ
distinguish
patient
icu
admiss
necessari
present
set
guidelin
new
set
criteria
develop
basi
data
individu
risk
although
previou
at
criteria
format
retain
addit
major
criteria
need
mechan
ventil
septic
shock
expand
set
minor
criteria
respiratori
rate
breathsmin
arteri
oxygen
pressurefract
inspir
oxygen
ratio
multilobar
infiltr
confus
blood
urea
nitrogen
level
mgdl
leukopenia
result
infect
thrombocytopenia
hypothermia
hypotens
requir
aggress
fluid
resuscit
propos
tabl
presenc
least
criteria
suggest
need
icu
care
requir
prospect
valid
addit
constel
suggest
clinic
featur
demonstr
infiltr
chest
radiograph
imag
techniqu
without
support
microbiolog
data
requir
diagnosi
pneumonia
moder
recommend
level
iii
evid
patient
cap
investig
specif
pathogen
would
significantli
alter
standard
empir
manag
decis
presenc
pathogen
suspect
basi
clinic
epidemiolog
clue
strong
recommend
level
ii
evid
recommend
diagnost
test
remain
controversi
overal
low
yield
infrequ
posit
impact
clinic
care
argu
routin
use
common
test
blood
sputum
cultur
convers
cultur
may
major
impact
care
individu
patient
import
epidemiolog
reason
includ
antibiot
suscept
pattern
use
develop
treatment
guidelin
list
clinic
indic
extens
diagnost
test
tabl
therefor
develop
primarili
basi
criteria
result
like
chang
individu
antibiot
manag
test
like
highest
yield
routin
diagnost
test
identifi
etiolog
diagnosi
option
outpati
cap
moder
recommend
level
iii
evid
pretreat
blood
sampl
cultur
expector
sputum
sampl
stain
cultur
patient
product
cough
obtain
hospit
patient
clinic
indic
list
tabl
option
patient
without
condit
moder
recommend
level
evid
pretreat
gram
stain
cultur
expector
sputum
perform
goodqual
specimen
obtain
qualiti
perform
measur
collect
transport
process
sampl
met
moder
recommend
level
ii
evid
patient
sever
cap
defin
least
blood
sampl
drawn
cultur
urinari
antigen
test
legionella
pneumophila
streptococcu
pneumonia
perform
expector
sputum
sampl
collect
cultur
intub
patient
endotrach
aspir
sampl
obtain
moder
recommend
level
ii
evid
clearcut
indic
extens
diagnost
test
critic
ill
cap
patient
patient
least
blood
drawn
cultur
endotrach
aspir
obtain
intub
consider
given
extens
test
includ
urinari
antigen
test
l
pneumophila
pneumonia
gram
stain
cultur
expector
sputum
nonintub
patient
inpati
without
clinic
indic
list
tabl
diagnost
test
option
consid
wrong
empir
antimicrobi
therapyempir
antibiot
recommend
tabl
chang
significantli
previou
guidelin
increas
evid
strengthen
recommend
combin
empir
therapi
sever
cap
recent
releas
antibiot
ad
recommend
ertapenem
accept
altern
hospit
patient
risk
factor
infect
gramneg
pathogen
pseudomona
aeruginosa
present
committe
await
evalu
safeti
telithromycin
us
food
drug
administr
make
final
recommend
regard
drug
recommend
gener
class
antibiot
rather
specif
drug
unless
outcom
data
clearli
favor
one
drug
overal
efficaci
remain
good
mani
class
agent
potent
drug
given
prefer
benefit
decreas
risk
select
antibiot
resist
previous
healthi
risk
factor
drugresist
pneumonia
drsp
infect
macrolid
azithromycin
clarithromycin
erythromycin
strong
recommend
level
evid
doxycyclin
weak
recommend
level
iii
evid
presenc
comorbid
chronic
heart
lung
liver
renal
diseas
diabet
mellitu
alcohol
malign
asplenia
immunosuppress
condit
use
immunosuppress
drug
use
antimicrobi
within
previou
month
case
altern
differ
class
select
risk
drsp
infect
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
strong
recommend
level
evid
b
plu
macrolid
strong
recommend
level
evid
highdos
amoxicillin
eg
g
time
daili
amoxicillinclavulan
g
time
daili
prefer
altern
includ
ceftriaxon
cefpodoxim
cefuroxim
mg
time
daili
doxycyclin
level
ii
evid
altern
macrolid
region
high
rate
infect
highlevel
mic
macrolideresist
pneumonia
consid
use
altern
agent
list
recommend
patient
includ
without
comorbid
moder
recommend
level
iii
evid
respiratori
fluoroquinolon
strong
recommend
level
evid
plu
macrolid
strong
recommend
level
evid
prefer
agent
includ
cefotaxim
ceftriaxon
ampicillin
ertapenem
select
patient
doxycyclin
level
iii
evid
altern
macrolid
respiratori
fluoroquinolon
use
penicillinallerg
patient
increas
resist
rate
suggest
empir
therapi
macrolid
alon
use
treatment
care
select
hospit
patient
nonsever
diseas
without
risk
factor
infect
drugresist
pathogen
howev
monotherapi
routin
recommend
inpati
icu
treatment
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
level
ii
evid
fluoroquinolon
level
evid
strong
recommend
penicillinallerg
patient
respiratori
fluoroquinolon
aztreonam
recommend
pseudomona
infect
use
antipneumococc
antipseudomon
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
dose
plu
aminoglycosid
azithromycin
plu
aminoglycosid
antipneumococc
fluoroquinolon
penicillinallerg
patient
substitut
aztreonam
moder
recommend
level
iii
evid
communityacquir
methicillinresist
staphylococcu
aureu
infect
add
vancomycin
linezolid
moder
recommend
level
iii
evid
infect
overwhelm
major
cap
pathogen
adequ
treat
use
recommend
empir
regimen
emerg
methicillinresist
aureu
cap
pathogen
small
signific
incid
cap
due
p
aeruginosa
except
pathogen
occur
specif
epidemiolog
pattern
andor
certain
clinic
present
empir
antibiot
coverag
may
warrant
howev
diagnost
test
like
high
yield
pathogen
allow
earli
discontinu
empir
treatment
result
neg
risk
factor
includ
tabl
recommend
indic
increas
diagnost
testingpathogen
suspect
basi
epidemiolog
consider
risk
factor
uncommon
etiolog
cap
list
tabl
recommend
treatment
includ
tabl
etiolog
cap
identifi
basi
reliabl
microbiolog
method
antimicrobi
therapi
direct
pathogen
moder
recommend
level
iii
evid
earli
treatment
within
h
onset
symptom
oseltamivir
zanamivir
recommend
influenza
strong
recommend
level
evid
use
oseltamivir
zanamivir
recommend
patient
uncompl
influenza
symptom
h
level
evid
drug
may
use
reduc
viral
shed
hospit
patient
influenza
pneumonia
moder
recommend
level
iii
evid
patient
ill
compat
influenza
known
exposur
poultri
area
previou
infect
test
infect
moder
recommend
level
iii
evid
patient
suspect
infect
droplet
precaut
care
routin
infect
control
measur
use
infect
rule
moder
recommend
level
iii
evid
patient
suspect
infect
treat
oseltamivir
level
ii
evid
antibacteri
agent
target
pneumonia
aureu
common
caus
secondari
bacteri
pneumonia
patient
influenza
level
iii
evid
moder
recommend
patient
admit
emerg
depart
ed
first
antibiot
dose
administ
still
ed
moder
recommend
level
iii
evid
rather
design
specif
window
initi
treatment
committe
felt
hospit
patient
cap
receiv
first
antibiot
dose
ed
switch
intraven
oral
therapi
patient
switch
intraven
oral
therapi
hemodynam
stabl
improv
clinic
abl
ingest
medic
normal
function
gastrointestin
tract
strong
recommend
level
ii
evid
patient
discharg
soon
clinic
stabl
activ
medic
problem
safe
environ
continu
care
inpati
observ
receiv
oral
therapi
necessari
moder
recommend
level
ii
evid
patient
cap
treat
minimum
day
level
evid
afebril
h
capassoci
sign
clinic
instabl
tabl
discontinu
therapi
level
ii
evid
moder
recommend
longer
durat
therapi
may
need
initi
therapi
activ
identifi
pathogen
complic
extrapulmonari
infect
mening
endocard
weak
recommend
level
iii
evid
patient
cap
persist
septic
shock
despit
adequ
fluid
resuscit
consid
treatment
drotrecogin
alfa
activ
within
h
admiss
weak
recommend
level
ii
evid
hypotens
fluidresuscit
patient
sever
cap
screen
occult
adren
insuffici
moder
recommend
level
ii
evid
patient
hypoxemia
respiratori
distress
receiv
cautiou
trial
noninvas
ventil
unless
requir
immedi
intub
sever
hypoxemia
ratio
bilater
alveolar
infiltr
moder
recommend
level
evid
lowtidalvolum
ventil
ideal
bodi
weight
use
patient
undergo
ventil
diffus
bilater
pneumonia
acut
respiratori
distress
syndrom
strong
recommend
level
evid
use
systemat
classif
possibl
caus
failur
respond
base
time
onset
type
failur
tabl
recommend
moder
recommend
level
ii
evid
mani
patient
cap
may
respond
appropri
initi
antibiot
therapi
systemat
approach
patient
tabl
help
determin
caus
determin
caus
failur
accur
origin
microbiolog
etiolog
known
risk
factor
nonrespons
deterior
tabl
figur
promin
list
situat
aggress
andor
extens
initi
diagnost
test
warrant
tabl
person
year
age
other
risk
influenza
complic
household
contact
highrisk
person
health
care
worker
receiv
inactiv
influenza
vaccin
recommend
advisori
committe
immun
practic
center
diseas
control
prevent
strong
recommend
level
evid
intranas
administ
live
attenu
vaccin
altern
vaccin
formul
person
year
age
without
chronic
underli
diseas
includ
immunodefici
asthma
chronic
medic
condit
strong
recommend
level
evid
health
care
worker
inpati
outpati
set
longterm
care
facil
receiv
annual
influenza
immun
strong
recommend
level
evid
pneumococc
polysaccharid
vaccin
recommend
person
year
age
select
highrisk
concurr
diseas
accord
current
advisori
committe
immun
practic
guidelin
strong
recommend
level
ii
evid
vaccin
statu
assess
time
hospit
admiss
patient
especi
medic
ill
moder
recommend
level
iii
evid
vaccin
may
perform
either
hospit
discharg
outpati
treatment
moder
recommend
level
iii
evid
influenza
vaccin
offer
person
hospit
discharg
outpati
treatment
fall
winter
strong
recommend
level
iii
evid
smoke
cessat
goal
person
hospit
cap
smoke
moder
recommend
level
iii
evid
smoker
quit
also
vaccin
pneumococcu
influenza
weak
recommend
level
iii
evid
case
pneumonia
public
health
concern
report
immedi
state
local
health
depart
strong
recommend
level
iii
evid
respiratori
hygien
measur
includ
use
hand
hygien
mask
tissu
patient
cough
use
outpati
set
ed
mean
reduc
spread
respiratori
infect
strong
recommend
level
iii
evid
improv
care
patient
communityacquir
pneumonia
cap
focu
mani
differ
organ
effort
improv
care
warrant
cap
togeth
influenza
remain
seventh
lead
caus
death
unit
state
accord
one
estim
episod
cap
occur
adult
year
age
year
unit
state
despit
advanc
antimicrobi
therapi
rate
mortal
due
pneumonia
decreas
significantli
sinc
penicillin
becam
routin
avail
group
interest
approach
manag
cap
includ
profession
societi
american
thorac
societi
at
infecti
diseas
societi
america
idsa
govern
agenc
contract
agent
center
medicar
medicaid
servic
depart
veteran
affair
voluntari
accredit
agenc
joint
commiss
accredit
healthcar
organ
addit
extern
review
group
consum
group
chosen
cap
outcom
major
qualiti
indic
interest
result
numer
guidelin
manag
cap
guidelin
repres
truli
differ
perspect
includ
differ
health
care
system
avail
diagnost
tool
therapeut
agent
either
etiolog
antibiot
suscept
common
caus
microorgan
wide
referenc
guidelin
unit
state
publish
at
idsa
differ
real
imagin
at
idsa
guidelin
led
confus
individu
physician
well
group
use
publish
guidelin
rather
promulg
respons
concern
idsa
at
conven
joint
committe
develop
unifi
cap
guidelin
document
document
repres
consensu
member
societi
govern
council
approv
statementpurpos
scopeth
purpos
document
updat
clinician
regard
import
advanc
controversi
manag
patient
cap
committe
chose
address
cap
occur
immunocompromis
patient
includ
solid
organ
bone
marrow
stem
cell
transplant
recipi
patient
receiv
cancer
chemotherapi
longterm
day
highdos
corticosteroid
treatment
patient
congenit
acquir
immunodefici
infect
hiv
cell
count
although
mani
patient
may
infect
microorgan
pneumonia
children
year
age
also
address
substanti
overlap
exist
among
patient
guidelin
address
discuss
recent
publish
guidelin
health
careassoci
pneumonia
hcap
two
issu
pertin
increas
risk
infect
drugresist
isol
usual
cap
pathogen
streptococcu
pneumonia
increas
risk
infect
less
common
usual
hospitalassoci
pathogen
pseudomona
acinetobact
speci
methicillinresist
staphylococcu
aureu
mrsa
pneumonia
nonambulatori
resid
nurs
home
longterm
care
facil
epidemiolog
mirror
hospitalacquir
pneumonia
treat
accord
hcap
guidelin
howev
certain
patient
whose
condit
includ
design
hcap
better
serv
manag
accord
cap
guidelin
concern
specif
pathogen
exampl
longterm
dialysi
alon
risk
mrsa
infect
necessarili
predispos
patient
infect
hcap
pathogen
pseudomona
aeruginosa
acinetobact
speci
hand
certain
patient
chronic
obstruct
pulmonari
diseas
copd
greater
risk
infect
pseudomona
speci
mrsa
issu
discuss
specif
section
committe
start
premis
mortal
due
cap
decreas
therefor
place
greatest
emphasi
aspect
guidelin
associ
decreas
mortal
reason
document
focus
mainli
manag
minim
discuss
factor
pathophysiolog
pathogenesi
mechan
antibiot
resist
virul
factor
committe
recogn
major
patient
cap
care
primari
care
hospitalist
emerg
medicin
physician
guidelin
therefor
direct
primarili
committe
consist
infecti
diseas
pulmonari
critic
care
physician
interest
expertis
pulmonari
infect
expertis
committe
extens
literatur
evalu
suggest
guidelin
also
appropri
start
point
consult
type
physician
although
much
literatur
cite
origin
europ
guidelin
orient
toward
unit
state
canada
although
guidelin
gener
applic
part
world
local
antibiot
resist
pattern
drug
avail
variat
health
care
system
suggest
modif
guidelin
prudent
local
usemethodologyth
process
guidelin
develop
start
select
committe
cochair
presid
idsa
at
consult
leader
respect
societi
committe
cochair
charg
select
rest
committe
idsa
member
involv
develop
previou
idsa
cap
guidelin
wherea
at
member
chosen
consult
leadership
mycobacteria
tuberculosi
pulmonari
infect
assembl
input
chair
clinic
pulmonari
critic
care
assembl
committe
member
chosen
repres
differ
expertis
viewpoint
variou
topic
one
acknowledg
weak
document
lack
represent
primari
care
hospitalist
emerg
medicin
physician
cochair
gener
gener
outlin
topic
cover
circul
committe
member
input
confer
phone
call
use
review
topic
discuss
evid
grade
gener
aim
expect
document
topic
divid
committe
member
assign
cochair
charg
present
topic
initi
facetofac
meet
well
develop
preliminari
document
deal
topic
controversi
topic
assign
committe
member
societi
initi
facetofac
meet
major
committe
member
involv
present
controversi
topic
includ
admiss
decis
diagnost
strategi
antibiot
therapi
prolong
discuss
follow
present
consensu
regard
major
issu
achiev
move
next
topic
input
rest
committe
present
committe
member
assign
less
controversi
topic
prepar
initi
draft
section
includ
grade
evid
iter
draft
statement
develop
distribut
email
critiqu
follow
multipl
revis
primari
author
second
facetofac
meet
also
held
discuss
less
controversi
area
critiqu
initi
draft
gener
agreement
separ
topic
obtain
cochair
incorpor
separ
document
singl
statement
substanti
edit
style
consist
document
redistribut
committe
member
review
updat
new
inform
literatur
june
recommend
chang
review
committe
member
email
andor
confer
phone
call
incorpor
final
document
cochair
document
submit
societi
approv
societi
independ
select
review
chang
recommend
review
discuss
committe
incorpor
final
document
guidelin
submit
idsa
govern
council
at
board
director
final
approvalgrad
guidelin
recommendationsiniti
committe
decid
grade
strength
evid
use
scale
tabl
use
recent
guidelin
societi
respons
review
comment
matur
field
guidelin
develop
separ
grade
strength
recommend
ad
final
draft
extens
valid
criteria
grade
impract
use
stage
scale
similar
use
idsa
guidelin
document
familiar
mani
committe
member
therefor
chosen
strength
recommend
grade
strong
moder
weak
committe
member
independ
grade
recommend
basi
evid
also
expert
interpret
clinic
applic
final
grade
recommend
composit
individu
committe
member
grade
final
document
strong
recommend
requir
member
consid
strong
major
other
grade
moder
implic
strong
recommend
patient
receiv
intervent
signific
variabl
manag
patient
cap
well
document
use
guidelin
suggest
variabl
undesir
industri
model
suggest
variabl
per
se
undesir
may
alway
relev
medicin
model
account
substanti
variabl
among
patient
account
variabl
end
point
limit
care
patient
endstag
underli
diseas
present
cap
reason
committe
member
feel
strongli
complianc
guidelin
desir
goal
howev
rational
variat
strongli
recommend
guidelin
appar
medic
record
convers
moder
weak
recommend
suggest
even
major
would
follow
recommend
manag
mani
practition
may
deviat
guidelin
may
occur
varieti
reason
one
document
cover
variabl
set
uniqu
host
epidemiolog
pattern
may
dictat
altern
manag
strategi
physician
judgment
alway
supersed
guidelin
born
find
deviat
guidelin
greatest
treatment
patient
cap
admit
icu
addit
recommend
level
evid
support
therefor
legitim
topic
futur
research
subsequ
public
studi
document
care
deviat
guidelin
result
better
outcom
stimul
revis
guidelin
committe
anticip
occur
reason
at
idsa
leadership
commit
revis
guidelin
regular
basi
recogn
guidelin
may
use
measur
qualiti
care
hospit
individu
practition
although
guidelin
evid
base
committe
strongli
urg
deviat
necessarili
consid
substandard
care
unless
accompani
evid
wors
outcom
studi
popul
local
adapt
guidelin
implement
improv
process
care
variabl
relev
clinic
outcom
strong
recommend
level
evid
enthusiasm
develop
set
cap
guidelin
deriv
larg
part
evid
previou
cap
guidelin
led
improv
clinic
relev
outcom
protocol
design
vari
among
studi
prefer
random
parallel
group
design
use
small
minor
confirmatori
studi
use
random
parallel
group
precis
defin
treatment
still
need
consist
pattern
benefit
found
type
level
studiesdocu
benefitspublish
protocol
vari
primari
focu
comprehens
correspond
benefit
vari
one
studi
anoth
howev
impress
aspect
literatur
consist
benefici
effect
seen
clinic
relev
paramet
introduct
protocol
increas
complianc
publish
guidelin
decreas
mortal
introduct
guidelinebas
protocol
found
sever
studi
studi
patient
pneumonia
admit
implement
pneumonia
guidelin
demonstr
crude
mortal
rate
lower
guidelin
adjust
ci
compar
among
patient
treat
concurr
nonaffili
physician
implement
practic
guidelin
one
spanish
hospit
surviv
rate
day
higher
ci
baselin
comparison
hospit
without
overt
protocol
lower
mortal
seen
studi
although
differ
statist
signific
studi
document
lower
mortal
emphas
increas
number
patient
receiv
guidelinerecommend
antibiot
confirm
result
multivari
analysi
retrospect
review
focu
guidelin
hospit
number
less
ill
patient
admit
hospit
consist
found
lower
use
admiss
decis
support
prospect
studi
emerg
depart
ed
visit
hospit
random
pathway
convent
manag
found
admiss
rate
among
lowrisk
patient
pathway
hospit
decreas
patient
pneumonia
sever
index
psi
class
p
without
differ
patient
satisfact
score
rate
readmiss
calcul
psi
score
assign
risk
class
provid
oral
clarithromycin
home
nurs
followup
significantli
p
decreas
number
lowmortalityrisk
admiss
howev
patient
satisfact
among
outpati
lower
implement
guidelin
despit
survey
data
suggest
patient
would
prefer
outpati
treatment
patient
discharg
ed
requir
hospit
within
day
although
anoth
studi
show
lower
readmiss
rate
use
protocol
admiss
decis
support
deriv
at
guidelin
recommend
combin
outpati
antibiot
recommend
reduc
cap
hospit
rate
admiss
rate
diagnos
unchang
surprisingli
result
overal
cost
care
decreas
half
p
protocol
use
guidelin
decreas
durat
hospit
also
success
guidelin
implement
connecticut
hospit
decreas
mean
length
hospit
stay
lo
day
p
edbas
protocol
decreas
mean
lo
day
p
benefit
guidelin
implement
maintain
year
initi
studi
trial
random
physician
group
guidelin
alon
versu
guidelin
multifacet
implement
strategi
found
addit
implement
strategi
associ
decreas
durat
intraven
antibiot
therapi
lo
although
neither
decreas
statist
signific
sever
studi
use
guidelin
significantli
shorten
lo
averag
day
marker
process
care
also
chang
use
protocol
time
first
antibiot
dose
effect
decreas
cap
protocol
random
parallel
group
studi
introduc
pneumonia
guidelin
small
oklahoma
hospit
ident
protocol
implement
remain
hospit
second
phase
serial
measur
key
process
measur
show
signific
improv
time
first
antibiot
dose
variabl
first
initi
hospit
later
remain
hospit
implement
guidelin
ed
halv
time
initi
antibiot
dose
cap
guidelin
address
comprehens
set
element
process
care
rather
singl
element
isol
strong
recommend
level
iii
evid
common
studi
document
comprehens
protocol
develop
implement
rather
one
address
singl
aspect
cap
care
studi
document
simpli
chang
metric
time
first
antibiot
dose
associ
decreas
mortal
element
import
cap
guidelin
list
tabl
rapid
appropri
empir
antibiot
therapi
consist
associ
improv
outcom
also
includ
element
good
care
gener
medic
inpati
earli
mobil
prophylaxi
thromboembol
diseas
although
local
guidelin
need
includ
element
logic
constel
element
address
develop
local
cap
guidelin
direct
toward
improv
specif
clinic
relev
outcom
moder
recommend
level
iii
evid
institut
cap
protocol
guidelin
outcom
relev
individu
center
medic
system
address
first
unless
desir
chang
clinic
relev
outcom
exist
adher
guidelin
low
institut
resourc
commit
implement
guidelin
like
insuffici
guidelin
treatment
pneumonia
must
use
approach
differ
current
practic
must
success
implement
process
care
outcom
chang
exampl
rhew
et
al
design
guidelin
decreas
lo
unlik
chang
care
recommend
median
lo
longer
exist
lo
cap
studi
hospit
difficulti
implement
guidelin
chang
physician
behavior
also
document
clinic
relev
outcom
paramet
evalu
measur
effect
local
guidelin
outcom
paramet
use
measur
effect
implement
cap
guidelin
within
organ
list
tabl
import
focu
one
aspect
care
studi
one
outcom
also
import
improv
one
area
may
offset
worsen
relat
area
exampl
decreas
admiss
lowacu
patient
might
increas
number
return
visit
ed
hospit
readmiss
almost
major
decis
regard
manag
cap
includ
diagnost
treatment
issu
revolv
around
initi
assess
sever
therefor
organ
guidelin
address
issu
firsthospit
admiss
decisionth
initi
manag
decis
diagnosi
determin
site
hospit
medic
ward
admiss
icu
decis
admit
patient
costli
issu
manag
cap
cost
inpati
care
pneumonia
time
greater
outpati
care
consum
major
estim
billion
spent
yearli
treatment
reason
avoid
unnecessari
admiss
patient
low
risk
death
treat
outpati
set
abl
resum
normal
activ
sooner
hospit
report
prefer
outpati
therapi
hospit
also
increas
risk
thromboembol
event
superinfect
morevirul
resist
hospit
bacteria
severityofil
score
criteria
confus
uremia
respiratori
rate
low
blood
pressur
age
year
greater
prognost
model
psi
use
identifi
patient
cap
may
candid
outpati
treatment
strong
recommend
level
evid
signific
variat
admiss
rate
among
hospit
among
individu
physician
well
document
physician
often
overestim
sever
hospit
signific
number
patient
low
risk
death
issu
interest
object
siteofcar
criteria
led
attempt
number
group
develop
criteria
rel
merit
limit
variou
propos
criteria
care
evalu
interest
psi
british
thorac
societi
bt
criteria
psi
base
deriv
valid
cohort
hospit
patient
cap
respect
plu
addit
combin
inpati
outpati
psi
stratifi
patient
mortal
risk
class
abil
predict
mortal
confirm
multipl
subsequ
studi
basi
associ
mortal
rate
suggest
risk
class
ii
patient
treat
outpati
risk
class
iii
patient
treat
observ
unit
short
hospit
risk
class
iv
v
patient
treat
inpati
yeali
et
al
conduct
clusterrandom
trial
low
moder
highintens
process
guidelin
implement
ed
unit
state
guidelin
use
psi
admiss
decis
support
includ
recommend
antibiot
therapi
time
first
antibiot
dose
measur
oxygen
satur
blood
cultur
admit
patient
ed
moder
highintens
guidelin
implement
demonstr
outpati
treatment
lowrisk
patient
higher
complianc
antibiot
recommend
differ
found
mortal
rate
rate
hospit
median
time
return
work
usual
activ
patient
satisfact
studi
differ
report
mortal
rate
differ
mani
hospit
patient
pneumonia
includ
addit
ed
lowintens
guidelin
implement
form
comparison
group
rather
ed
practic
nonguidelin
usual
pneumonia
care
bt
origin
criteria
subsequ
modifi
initi
studi
risk
death
increas
patient
time
admiss
least
follow
condit
tachypnea
diastol
hypotens
elev
blood
urea
nitrogen
bun
level
criteria
appear
function
well
except
among
patient
underli
renal
insuffici
among
elderli
patient
recent
modif
bt
criteria
includ
easili
measur
factor
multivari
analysi
patient
identifi
follow
factor
indic
increas
mortal
confus
base
specif
mental
test
disorient
person
place
time
bun
level
mmoll
mgdl
respiratori
rate
breathsmin
low
blood
pressur
systol
mm
hg
diastol
mm
hg
age
year
gave
rise
acronym
deriv
valid
cohort
mortal
among
patient
factor
respect
mortal
higher
factor
present
report
respect
author
suggest
patient
score
treat
outpati
score
admit
ward
patient
score
often
requir
icu
care
simplifi
version
requir
test
bun
level
may
appropri
decis
make
primari
care
practition
offic
use
object
admiss
criteria
clearli
decreas
number
patient
hospit
cap
whether
psi
score
superior
unclear
random
trial
altern
admiss
criteria
exist
compar
popul
psi
classifi
slightli
larger
percentag
patient
cap
lowrisk
categori
compar
curb
criteria
remain
associ
similar
low
mortal
rate
among
patient
categor
low
risk
sever
factor
import
comparison
psi
includ
differ
variabl
therefor
reli
avail
score
sheet
limit
practic
busi
ed
contrast
criteria
easili
rememb
howev
extens
studi
psi
especi
prospect
valid
patient
popul
eg
indig
innerc
popul
specif
studi
mean
reduc
hospit
admiss
rate
ed
suffici
decis
support
resourc
either
human
computer
benefit
greater
experi
psi
score
may
favor
use
screen
patient
may
candid
outpati
manag
object
criteria
score
alway
supplement
physician
determin
subject
factor
includ
abil
safe
reliabl
take
oral
medic
avail
outpati
support
resourc
strong
recommend
level
ii
evid
studi
show
certain
patient
low
psi
score
requir
hospit
admiss
even
icu
score
depend
certain
assumpt
one
main
rational
admiss
patient
cap
risk
death
assumpt
clearli
valid
case
anoth
laboratori
vital
sign
use
score
stabl
time
rather
indic
transient
abnorm
also
true
case
therefor
dynam
assess
sever
hour
observ
may
accur
score
deriv
singl
point
time
although
advantag
make
decis
regard
hospit
admiss
sole
relianc
score
hospit
admiss
decis
unsaf
reason
admiss
lowmortalityrisk
patient
fall
categori
complic
pneumonia
exacerb
underli
diseas
inabl
reliabl
take
oral
medic
receiv
outpati
care
andor
multipl
risk
factor
fall
threshold
score
use
psi
score
clinic
trial
demonstr
limit
may
equal
applic
score
techniqu
modif
origin
psi
score
need
appli
admiss
decis
arteri
satur
arteri
oxygen
pressur
mm
hg
complic
pneumonia
ad
sole
indic
admiss
patient
risk
class
ad
margin
safeti
one
trial
addit
patient
requir
hospit
admiss
hypoxemia
subsequ
studi
identifi
patient
low
psi
risk
class
need
hospit
admiss
shock
decompens
coexist
ill
pleural
effus
inabl
maintain
oral
intak
social
problem
patient
depend
caregiv
avail
lack
respons
previou
adequ
empir
antibiot
therapi
patient
low
psi
risk
class
treat
inpati
present
least
factor
medic
psychosoci
need
requir
hospit
care
includ
intract
vomit
inject
drug
abus
sever
psychiatr
ill
homeless
poor
overal
function
statu
cognit
dysfunct
psi
score
base
histori
diseas
increas
risk
death
wherea
score
directli
address
underli
diseas
howev
pneumonia
may
exacerb
underli
diseas
obstruct
lung
diseas
congest
heart
failur
diabet
mellitu
may
requir
hospit
admiss
atla
et
al
abl
reduc
hospit
admiss
among
patient
psi
risk
class
retrospect
control
group
psibas
intervent
group
ten
patient
latter
group
compar
patient
control
popul
subsequ
admit
sever
reason
unrel
pneumonia
also
presenc
rare
ill
neuromuscular
sickl
cell
diseas
may
requir
hospit
affect
psi
score
necessari
relianc
dichotom
predictor
variabl
abnorm
vs
normal
criteria
heavi
relianc
age
surrog
psi
score
may
oversimplifi
use
admiss
decis
exampl
previous
healthi
patient
sever
hypotens
tachycardia
addit
pertin
prognost
factor
would
place
risk
class
ii
wherea
man
histori
local
prostat
cancer
diagnos
month
earlier
problem
would
place
risk
class
iv
final
patient
satisfact
lower
among
patient
treat
outsid
hospit
one
studi
psibas
intervent
group
suggest
save
result
use
psi
may
overestim
physician
consid
addit
factor
measur
psi
patient
score
moreintens
hospit
appropri
avail
intens
inhom
health
care
usual
warrant
moder
recommend
level
iii
evid
although
psi
criteria
valuabl
aid
avoid
inappropri
admiss
lowmortalityrisk
patient
anoth
import
role
criteria
may
help
identifi
patient
high
risk
would
benefit
hospit
committe
prefer
criteria
eas
use
design
measur
ill
sever
likelihood
mortal
patient
score
increas
risk
death
also
like
clinic
import
physiolog
derang
requir
activ
intervent
patient
usual
consid
hospit
aggress
inhom
care
avail
cohort
patient
mortal
score
wherea
point
associ
mortal
psi
score
base
directli
sever
ill
criteria
threshold
patient
would
requir
hospit
admiss
intens
outpati
treatment
harder
defin
higher
score
greater
need
hospit
howev
even
patient
meet
criteria
risk
class
v
basi
old
age
multipl
stabl
chronic
ill
may
success
manag
outpati
icu
admiss
decis
direct
admiss
icu
requir
patient
septic
shock
requir
vasopressor
acut
respiratori
failur
requir
intub
mechan
ventil
strong
recommend
level
ii
evid
direct
admiss
icu
highlevel
monitor
unit
recommend
patient
minor
criteria
sever
cap
list
tabl
moder
recommend
level
ii
evid
secondlevel
admiss
decis
whether
place
patient
icu
highlevel
monitor
unit
rather
gener
medic
floor
approxim
hospit
patient
cap
requir
icu
admiss
indic
vari
strikingli
among
patient
physician
hospit
differ
health
care
system
variabl
among
institut
result
avail
highlevel
monitor
intermedi
care
unit
appropri
patient
increas
risk
complic
respiratori
failur
major
reason
delay
transfer
icu
simpl
cardiac
monitor
unit
would
meet
criteria
highlevel
monitor
unit
patient
sever
cap
one
import
determin
need
icu
care
presenc
chronic
comorbid
condit
howev
approxim
onethird
patient
sever
cap
previous
healthi
rational
specif
defin
sever
cap
appropri
placement
patient
optim
use
limit
icu
resourc
transfer
icu
delay
respiratori
failur
delay
onset
septic
shock
associ
increas
mortal
although
lowacu
icu
admiss
occur
major
concern
initi
admiss
gener
medic
unit
subsequ
transfer
icu
mani
patient
cap
ultim
requir
icu
admiss
initi
admit
nonicu
set
mani
delay
transfer
icu
repres
rapidli
progress
pneumonia
obviou
admiss
howev
subtl
find
includ
includ
minor
criteria
tabl
might
warrant
direct
admiss
icu
distribut
microbi
etiolog
differ
cap
gener
signific
implic
diagnost
test
empir
antibiot
choic
avoid
inappropri
antibiot
therapi
also
associ
lower
mortal
patient
cap
appropri
immunomodulatori
treatment
must
identifi
system
inflammatori
responsesever
sepsi
criteria
typic
use
gener
sepsi
trial
may
adequ
appli
specif
sever
cap
exampl
patient
unilater
lobar
pneumonia
may
hypoxemia
sever
enough
meet
criteria
acut
lung
injuri
system
respons
sever
criteria
propos
defin
sever
cap
case
seri
defin
simpli
cap
necessit
icu
admiss
object
criteria
identifi
patient
icu
admiss
includ
initi
at
definit
sever
cap
subsequ
modif
curb
criteria
psi
sever
class
v
iv
v
howev
none
criteria
prospect
valid
icu
admiss
decis
recent
criteria
retrospect
evalu
cohort
patient
cap
admit
icu
found
overli
sensit
nonspecif
comparison
origin
clinic
decis
admit
icu
revis
criteria
altern
criteria
therefor
recommend
revis
criteria
structur
modifi
at
criteria
sever
cap
retain
major
ventil
endotrach
intub
septic
shock
requir
absolut
indic
admiss
icu
contrast
need
icu
admiss
less
straightforward
patient
meet
major
criteria
basi
publish
oper
characterist
criteria
singl
set
minor
criteria
adequ
defin
sever
cap
at
minor
criteria
curb
criteria
valid
predict
patient
increas
risk
death
therefor
at
minor
criteria
curb
variabl
includ
new
propos
minor
criteria
tabl
age
felt
appropri
factor
icu
admiss
decis
remaind
criteria
retain
minor
criteria
except
hypotens
requir
vasopressor
major
criterion
rather
complex
criteria
confus
origin
curb
studi
definit
confus
newonset
disorient
person
place
time
three
addit
minor
criteria
ad
leukopenia
white
blood
cell
count
result
cap
consist
associ
excess
mortal
well
increas
risk
complic
acut
respiratori
distress
syndrom
ard
addit
leukopenia
seen
bacterem
pneumococc
diseas
also
gramneg
cap
leukopenia
occur
patient
histori
alcohol
abus
advers
manifest
septic
shock
ard
may
delay
mask
therefor
patient
thought
benefit
icu
monitor
coagul
system
often
activ
cap
develop
thrombocytopenia
platelet
count
also
associ
wors
prognosi
nonexposur
hypothermia
core
temperatur
also
carri
omin
prognosi
cap
committe
felt
suffici
justif
includ
addit
factor
minor
criteria
factor
associ
increas
mortal
due
cap
also
consid
includ
acut
alcohol
ingest
delirium
tremen
hypoglycemia
hyperglycemia
occult
metabol
acidosi
elev
lactat
level
hyponatremia
howev
mani
criteria
overlap
select
futur
studi
valid
propos
criteria
record
factor
well
determin
whether
addit
substitut
improv
predict
valu
propos
criteria
addit
minor
criteria
threshold
icu
admiss
felt
presenc
least
minor
criteria
base
mortal
associ
curb
criteria
select
criteria
appear
nonspecif
demonstr
initi
at
criteria
whether
criteria
equal
weight
also
clear
therefor
prospect
valid
set
criteria
clearli
need
patient
cap
investig
specif
pathogen
would
significantli
alter
standard
empir
manag
decis
presenc
pathogen
suspect
basi
clinic
epidemiolog
clue
strong
recommend
level
ii
evid
need
diagnost
test
determin
etiolog
cap
justifi
sever
perspect
primari
reason
test
result
chang
antibiot
manag
individu
patient
spectrum
antibiot
therapi
broaden
narrow
complet
alter
basi
diagnost
test
alter
therapi
potenti
benefici
individu
escal
switch
usual
empir
regimen
unusu
pathogen
eg
endem
fungi
mycobacterium
tuberculosi
antibiot
resist
issu
broad
empir
coverag
recommend
guidelin
would
provid
optim
treatment
certain
infect
psittacosi
tularemia
increas
mortal
increas
risk
clinic
failur
common
inappropri
antibiot
therapi
manag
initi
antibiot
failur
greatli
facilit
etiolog
diagnosi
admiss
deescal
narrow
antibiot
therapi
basi
diagnost
test
less
like
decreas
individu
risk
death
may
decreas
cost
drug
advers
effect
antibiot
resist
pressur
etiolog
diagnos
import
epidemiolog
implic
document
sever
acut
respiratori
syndrom
sar
influenza
legionnair
diseas
agent
bioterror
diagnost
test
infect
may
affect
individu
also
mani
peopl
although
pneumonia
etiolog
report
public
health
offici
vari
state
gener
state
health
regul
requir
report
legionnair
diseas
sar
psittacosi
avian
influenza
possibl
agent
bioterror
plagu
tularemia
anthrax
addit
specif
diagnost
test
report
import
pneumonia
case
etiolog
thought
part
cluster
caus
pathogen
endem
area
also
societ
reason
encourag
diagnost
test
antibiot
recommend
present
guidelin
base
cultur
result
sensit
pattern
patient
posit
etiolog
diagnos
without
accumul
inform
avail
cultur
result
trend
antibiot
resist
difficult
track
empir
antibiot
recommend
less
like
accur
main
downsid
extens
diagnost
test
patient
cap
cost
driven
poor
qualiti
sputum
microbiolog
sampl
low
yield
posit
cultur
result
mani
group
patient
cap
clear
need
improv
diagnost
test
cap
like
use
molecular
methodolog
rather
cultur
recogn
nation
institut
health
costbenefit
ratio
even
wors
antibiot
therapi
streamlin
possibl
inappropri
escal
occur
clinic
practic
narrow
antibiot
therapi
unfortun
unusu
committe
strongli
recommend
best
medic
practic
possibl
polymicrobi
cap
potenti
benefit
combin
therapi
bacterem
pneumococc
pneumonia
complic
decis
narrow
antibiot
therapi
delay
start
antibiot
therapi
result
need
obtain
specimen
complic
invas
diagnost
procedur
unneed
antibiot
chang
addit
test
falseposit
test
also
import
consider
gener
recommend
committe
strongli
encourag
diagnost
test
whenev
result
like
chang
individu
antibiot
manag
patient
cap
recommend
diagnost
test
focu
patient
diagnost
yield
thought
greatest
prioriti
often
overlap
recommend
patient
routin
diagnost
test
indic
reason
list
tabl
emphasi
clinic
relev
varieti
diagnost
test
may
accur
result
avail
time
window
allow
clinic
decis
neither
recommend
discuss
routin
diagnost
test
identifi
etiolog
diagnosi
option
outpati
cap
moder
recommend
level
iii
evid
retrospect
studi
outpati
cap
manag
usual
show
diagnost
test
defin
etiolog
pathogen
infrequ
perform
yet
patient
well
empir
antibiot
treatment
except
gener
rule
may
appli
pathogen
import
epidemiolog
reason
manag
decis
avail
rapid
pointofcar
diagnost
test
specif
treatment
chemoprevent
epidemiolog
import
make
influenza
test
logic
influenza
often
suspect
basi
typic
symptom
proper
season
presenc
epidem
howev
respiratori
syncyti
viru
rsv
caus
similar
syndrom
often
occur
clinic
scenario
rapid
diagnost
test
may
indic
diagnosi
uncertain
distinguish
influenza
influenza
b
import
therapeut
decis
infect
import
verifi
diagnost
studi
epidemiolog
implic
requir
uniqu
therapeut
intervent
sar
avian
influenza
diseas
caus
agent
bioterror
legionella
infect
communityacquir
mrsa
camrsa
infect
tuberculosi
infect
endem
fungal
infect
attempt
establish
etiolog
diagnosi
also
appropri
select
case
associ
outbreak
specif
risk
factor
atyp
present
pretreat
blood
sampl
cultur
expector
sputum
sampl
stain
cultur
patient
product
cough
obtain
hospit
patient
clinic
indic
list
tabl
option
patient
without
condit
moder
recommend
level
evid
pretreat
gram
stain
cultur
expector
sputum
perform
goodqual
specimen
obtain
qualiti
perform
measur
collect
transport
process
sampl
met
moder
recommend
level
ii
evid
patient
sever
cap
defin
least
blood
sampl
drawn
cultur
urinari
antigen
test
legionella
pneumophila
pneumonia
perform
expector
sputum
sampl
collect
cultur
intub
patient
endotrach
aspir
sampl
obtain
moder
recommend
level
ii
evid
random
control
trial
diagnost
strategi
cap
demonstr
statist
signific
differ
mortal
rate
lo
patient
receiv
pathogendirect
therapi
patient
receiv
empir
therapi
howev
pathogendirect
therapi
associ
lower
mortal
among
small
number
patient
admit
icu
studi
perform
countri
low
incid
antibiot
resist
may
limit
applic
area
higher
level
resist
advers
effect
significantli
common
empir
therapi
group
may
uniqu
specif
antibiot
choic
erythromycin
lack
benefit
overal
trial
interpret
lack
benefit
individu
patient
therefor
perform
diagnost
test
never
incorrect
breach
standard
care
howev
inform
cohort
observ
studi
may
use
defin
patient
group
diagnost
yield
increas
patient
group
routin
diagnost
test
indic
recommend
test
list
tabl
culturespretreat
blood
cultur
yield
posit
result
probabl
pathogen
larg
seri
nonselect
patient
hospit
cap
yield
blood
cultur
therefor
rel
low
although
similar
yield
seriou
infect
manag
decis
analyz
impact
posit
blood
cultur
minor
common
blood
cultur
isol
cap
studi
pneumonia
bacteri
organ
alway
consid
like
pathogen
posit
blood
cultur
result
clearli
led
better
outcom
improv
antibiot
select
falseposit
blood
cultur
result
associ
prolong
hospit
stay
possibl
relat
chang
manag
base
preliminari
result
show
gramposit
cocci
eventu
prove
coagulaseneg
staphylococci
addit
falseposit
blood
cultur
result
led
significantli
vancomycin
use
reason
blood
cultur
option
hospit
patient
cap
perform
select
tabl
yield
posit
blood
cultur
result
halv
prior
antibiot
therapi
therefor
perform
sampl
blood
cultur
obtain
antibiot
administr
howev
multipl
risk
factor
bacteremia
present
blood
cultur
result
initi
antibiot
therapi
still
posit
case
therefor
still
warrant
case
despit
lower
yield
strongest
indic
blood
cultur
sever
cap
patient
sever
cap
like
infect
pathogen
pneumonia
includ
aureu
p
aeruginosa
gramneg
bacilli
mani
factor
predict
posit
blood
cultur
result
overlap
risk
factor
sever
cap
tabl
therefor
blood
cultur
recommend
patient
sever
cap
higher
yield
greater
possibl
presenc
pathogen
cover
usual
empir
antibiot
therapi
increas
potenti
affect
antibiot
manag
blood
cultur
also
indic
patient
host
defect
abil
clear
exampl
result
asplenia
complement
defici
patient
chronic
liver
diseas
also
like
bacteremia
cap
leukopenia
also
associ
high
incid
bacteremia
respiratori
tract
specimen
gram
stain
cultureth
yield
sputum
bacteri
cultur
variabl
strongli
influenc
qualiti
entir
process
includ
specimen
collect
transport
rapid
process
satisfactori
use
cytolog
criteria
absenc
prior
antibiot
therapi
skill
interpret
yield
pneumonia
exampl
sputum
cultur
patient
bacterem
pneumococc
pneumonia
studi
perform
decad
ago
recent
studi
case
bacterem
pneumococc
pneumonia
found
sputum
specimen
submit
case
judg
inadequ
anoth
case
patient
receiv
antibiot
h
exclud
gram
stain
show
pneumococci
sputum
specimen
cultur
result
posit
patient
receiv
antibiot
gram
stain
read
consist
pneumococci
case
sputum
cultur
result
posit
although
favor
report
util
gram
stain
metaanalysi
show
low
yield
consid
number
patient
adequ
specimen
definit
result
recent
data
show
adequ
specimen
predomin
morphotyp
gram
stain
found
hospit
patient
cap
higher
psi
score
predict
higher
yield
howev
posit
gram
stain
highli
predict
subsequ
posit
cultur
result
benefit
sputum
gram
stain
therefor
first
broaden
initi
empir
coverag
less
common
etiolog
infect
aureu
gramneg
organ
indic
probabl
import
lead
less
inappropri
antibiot
therapi
second
valid
subsequ
sputum
cultur
result
forti
percent
patient
unabl
produc
sputum
produc
sputum
time
manner
yield
cultur
substanti
higher
endotrach
aspir
bronchoscop
sampl
transthorac
needl
aspir
although
specimen
obtain
initi
antibiot
therapi
unreli
must
interpret
care
interpret
improv
quantit
cultur
respiratori
secret
sourc
sputum
tracheal
aspir
bronchoscop
aspir
interpret
base
semiquantit
cultur
result
signific
influenc
diagnost
yield
cost
effect
care
attent
detail
specimen
handl
process
critic
sputum
cultur
obtain
best
specimen
collect
process
antibiot
given
time
consid
obtain
expector
sputum
specimen
patient
factor
list
tabl
initi
antibiot
therapi
best
indic
extens
respiratori
tract
cultur
sever
cap
gram
stain
cultur
endotrach
aspir
intub
patient
cap
produc
differ
result
expector
sputum
nonicu
patient
mani
pathogen
broader
microbiolog
spectrum
sever
cap
unaffect
singl
dose
antibiot
unlik
pneumonia
addit
endotrach
aspir
requir
patient
cooper
clearli
lower
respiratori
tract
sampl
less
like
contamin
oropharyng
colon
nosocomi
tracheal
colon
issu
sampl
obtain
soon
intub
therefor
cultur
gram
stain
endotrach
aspir
recommend
patient
intub
sever
cap
addit
routin
cultur
specif
request
cultur
respiratori
secret
buffer
charcoal
yeast
extract
agar
isol
legionella
speci
may
use
subset
patient
sever
cap
area
legionella
endem
well
patient
recent
travel
histori
fact
respiratori
tract
cultur
result
neg
mean
valu
failur
detect
aureu
gramneg
bacilli
goodqual
specimen
strong
evid
presenc
pathogen
growth
inhibit
antibiot
lower
pathogen
pneumonia
specimen
obtain
initi
antibiot
therapi
harder
interpret
possibl
colon
necrot
cavitari
pneumonia
risk
camrsa
infect
sputum
sampl
obtain
case
neg
gram
stain
cultur
result
adequ
withhold
stop
treatment
mrsa
infect
sever
copd
alcohol
major
risk
factor
infect
p
aeruginosa
gramneg
pathogen
gram
stain
cultur
adequ
sputum
specimen
usual
adequ
exclud
need
empir
coverag
pathogen
sputum
cultur
patient
suspect
legionnair
diseas
import
identif
legionella
speci
impli
possibl
environment
sourc
suscept
individu
may
expos
local
commun
outbreak
legionnair
diseas
might
recogn
clinician
local
health
depart
patient
might
admit
hospit
howev
outbreak
legionnair
diseas
associ
hotel
cruis
ship
rare
detect
individu
clinician
travel
typic
dispers
sourc
infect
develop
symptom
therefor
travel
histori
activ
sought
patient
cap
legionella
test
perform
travel
week
onset
symptom
urinari
antigen
test
may
adequ
diagnos
treat
individu
effort
obtain
sputum
specimen
cultur
still
indic
facilit
epidemiolog
track
avail
cultur
isol
legionella
dramat
improv
likelihood
environment
sourc
legionella
identifi
remedi
yield
sputum
cultur
increas
associ
posit
urinari
antigen
test
result
attempt
obtain
sampl
sputum
cultur
patient
posit
pneumococc
urinari
antigen
test
result
may
indic
similar
reason
patient
product
cough
posit
urinari
antigen
test
result
posit
sputum
cultur
result
mani
case
case
sensit
test
confirm
appropri
choic
individu
patient
import
data
regard
local
commun
antibiot
resist
rate
also
acquiredoth
culturespati
pleural
effus
cm
height
later
upright
chest
radiograph
undergo
thoracentesi
yield
materi
gram
stain
cultur
aerob
anaerob
bacteria
yield
pleural
fluid
cultur
low
impact
manag
decis
substanti
term
antibiot
choic
need
drainag
nonbronchoscop
bronchoalveolar
lavag
bal
ed
studi
small
random
trial
intub
patient
cap
high
percentag
nonbronchoscop
bal
cultur
result
posit
even
patient
alreadi
receiv
first
dose
antibiot
unfortun
tracheal
aspir
obtain
third
patient
control
group
cultur
posit
therefor
unclear
endotrach
aspir
inferior
nonbronchoscop
bal
use
bronchoscop
bal
protect
specimen
brush
transthorac
lung
aspir
prospect
studi
initi
manag
patient
cap
best
indic
immunocompromis
patient
cap
patient
cap
therapi
fail
antigen
testsurinari
antigen
test
commerci
avail
clear
us
food
drug
administr
fda
detect
pneumonia
l
pneumophila
serogroup
urinari
antigen
test
appear
higher
diagnost
yield
patient
sever
ill
pneumococc
pneumonia
princip
advantag
antigen
test
rapid
min
simplic
reason
specif
adult
abil
detect
pneumococc
pneumonia
antibiot
therapi
start
studi
adult
show
sensit
specif
attract
test
detect
pneumococc
pneumonia
sampl
cultur
obtain
time
fashion
antibiot
therapi
alreadi
initi
serial
specimen
patient
known
bacteremia
still
posit
pneumococc
urinari
antigen
case
day
therapi
comparison
gram
stain
show
rapidli
avail
test
often
overlap
concord
among
patient
result
either
test
posit
binax
pneumococc
urinari
antigenposit
patient
diagnos
convent
method
disadvantag
includ
cost
approxim
per
specimen
although
offset
increas
diagnosisrel
groupbas
reimburs
code
pneumococc
pneumonia
lack
organ
vitro
suscept
test
falseposit
result
seen
children
chronic
respiratori
diseas
colon
pneumonia
patient
episod
cap
within
previou
month
appear
signific
problem
colon
patient
copd
legionella
sever
urinari
antigen
assay
avail
detect
l
pneumophila
serogroup
although
particular
serogroup
account
communityacquir
case
legionnair
diseas
mani
area
north
america
speci
serogroup
predomin
specif
local
prior
studi
cultureproven
legionnair
diseas
indic
sensit
specif
nearli
detect
l
pneumophila
serogroup
urin
posit
antigen
day
ill
continu
posit
week
major
issu
urinari
bacteri
antigen
detect
whether
test
allow
narrow
empir
antibiot
therapi
singl
specif
agent
recommend
empir
antibiot
regimen
cover
microorgan
result
small
observ
studi
suggest
therapi
macrolid
alon
adequ
hospit
patient
cap
test
posit
l
pneumophila
urinari
antigen
research
need
area
contrast
rapid
antigen
detect
test
influenza
also
provid
etiolog
diagnosi
within
min
lead
consider
antivir
therapi
test
perform
vari
accord
test
use
sampl
type
durat
ill
patient
age
show
sensit
adult
specif
approach
advantag
includ
high
specif
abil
assay
distinguish
influenza
b
rapid
result
obtain
possibl
reduc
use
antibacteri
agent
util
establish
diagnosi
epidemiolog
purpos
especi
hospit
patient
may
requir
infect
control
precaut
disadvantag
includ
cost
approxim
per
specimen
high
rate
falseneg
test
result
falseposit
assay
adenoviru
infect
fact
sensit
superior
physician
judgment
among
patient
typic
symptom
influenza
epidem
direct
fluoresc
antibodi
test
avail
influenza
rsv
requir
h
influenza
viru
sensit
better
pointofcar
test
detect
anim
subtyp
thu
may
prefer
hospit
patient
rsv
direct
fluoresc
antibodi
test
insensit
sensit
adult
rare
valu
acutephas
serolog
testingth
standard
diagnosi
infect
atyp
pathogen
includ
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
speci
l
pneumophila
reli
acut
convalescentphas
serolog
test
studi
use
microimmunofluoresc
serolog
test
test
show
poor
reproduc
manag
patient
basi
singl
acutephas
titer
unreli
initi
antibiot
therapi
complet
earliest
time
point
check
convalescentphas
specimenpcra
new
pcr
test
bd
probetec
et
legionella
pneumophila
becton
dickinson
detect
serotyp
l
pneumophila
sputum
clear
fda
extens
publish
clinic
experi
lack
pcr
reagent
respiratori
pathogen
except
mycobacterium
speci
home
grown
requir
use
base
complianc
nccl
criteria
analyt
valid
despit
increas
use
test
atyp
pathogen
review
center
diseas
control
prevent
cdc
diagnost
assay
detect
c
pneumonia
indic
pcr
reagent
satisfi
criteria
valid
test
diagnost
criteria
defin
review
particularli
import
use
prospect
studi
cap
prior
report
use
liber
criteria
result
exagger
rate
sar
sever
pcr
assay
develop
test
inadequ
high
rate
falseneg
assay
earli
stage
infect
although
cap
may
caus
myriad
pathogen
limit
number
agent
respons
case
emerg
newli
recogn
pathogen
novel
sarsassoci
coronaviru
continu
increas
challeng
appropri
manag
tabl
list
common
caus
cap
decreas
order
frequenc
occurr
stratifi
sever
ill
judg
site
care
ambulatori
vs
hospit
pneumonia
frequent
isol
pathogen
bacteri
caus
includ
nontyp
haemophilu
influenza
moraxella
catarrhali
gener
patient
underli
bronchopulmonari
diseas
aureu
especi
influenza
outbreak
risk
infect
enterobacteriacea
speci
p
aeruginosa
etiolog
cap
chronic
oral
steroid
administr
sever
underli
bronchopulmonari
diseas
alcohol
frequent
antibiot
therapi
wherea
recent
hospit
would
defin
case
hcap
less
common
caus
pneumonia
includ
mean
limit
streptococcu
pyogen
neisseria
meningitidi
pasteurella
multocida
h
influenza
type
b
atyp
organ
call
detect
gram
stain
cultivat
standard
bacteriolog
media
includ
pneumonia
c
pneumonia
legionella
speci
respiratori
virus
except
legionella
speci
microorgan
common
caus
pneumonia
especi
among
outpati
howev
pathogen
often
identifi
clinic
practic
except
l
pneumophila
influenza
viru
specif
rapid
standard
test
detect
exist
although
influenza
remain
predomin
viral
caus
cap
adult
commonli
recogn
virus
includ
rsv
adenoviru
parainfluenza
viru
well
less
common
virus
includ
human
metapneumoviru
herp
simplex
viru
varicellazost
viru
sarsassoci
coronaviru
measl
viru
recent
studi
immunocompet
adult
patient
admit
hospit
cap
evid
viral
etiolog
respiratori
viru
pathogen
identifi
studi
includ
outpati
find
viral
pneumonia
rate
high
frequenc
etiolog
exampl
tuberculosi
chlamydophila
psittaci
psittacosi
coxiella
burnetii
q
fever
francisella
tularensi
tularemia
bordetella
pertussi
whoop
cough
endem
fungi
histoplasma
capsulatum
coccidioid
immiti
cryptococcu
neoforman
blastomyc
homini
larg
determin
epidemiolog
set
tabl
rare
exce
total
except
may
endem
fungi
appropri
geograph
distribut
need
specif
anaerob
coverag
cap
gener
overestim
anaerob
bacteria
detect
diagnost
techniqu
current
use
anaerob
coverag
clearli
indic
classic
aspir
pleuropulmonari
syndrom
patient
histori
loss
conscious
result
alcoholdrug
overdos
seizur
patient
concomit
gingiv
diseas
esophog
motil
disord
antibiot
trial
demonstr
need
specif
treat
organ
major
cap
case
smallvolum
aspir
time
intub
adequ
handl
standard
empir
sever
cap
treatment
high
oxygen
tension
provid
mechan
ventil
resist
commonli
use
antibiot
cap
present
anoth
major
consider
choos
empir
therapi
resist
pattern
clearli
vari
geographi
local
antibiot
prescrib
pattern
like
explan
howev
clonal
spread
resist
strain
well
document
therefor
antibiot
recommend
must
modifi
basi
local
suscept
pattern
reliabl
sourc
stateprovinci
municip
health
depart
region
data
avail
local
hospit
antibiogram
gener
access
sourc
data
may
suffer
small
number
isolatesdrugresist
pneumonia
drsp
emerg
drugresist
pneumococc
isol
well
document
incid
resist
appear
stabil
somewhat
past
year
resist
penicillin
cephalosporin
may
even
decreas
wherea
macrolid
resist
continu
increas
howev
clinic
relev
drsp
pneumonia
uncertain
wellcontrol
studi
examin
impact
vitro
resist
clinic
outcom
cap
publish
studi
limit
small
sampl
size
bias
inher
observ
design
rel
infrequ
isol
exhibit
highlevel
resist
current
level
resist
gener
result
cap
treatment
failur
appropri
agent
ie
amoxicillin
ceftriaxon
cefotaxim
dose
use
even
presenc
bacteremia
avail
data
suggest
clinic
relev
level
penicillin
resist
mic
least
mgl
one
report
suggest
cefuroxim
use
treat
pneumococc
bacteremia
organ
resist
vitro
outcom
wors
therapi
discord
therapi
includ
penicillin
impact
mortal
data
exist
suggest
resist
macrolid
older
fluoroquinolon
ciprofloxacin
levofloxacin
result
clinic
failur
date
failur
report
newer
fluoroquinolon
moxifloxacin
gemifloxacin
risk
factor
infect
pneumonia
includ
age
year
year
therapi
within
previou
month
alcohol
medic
comorbid
immunosuppress
ill
therapi
exposur
child
day
care
center
although
rel
predict
valu
risk
factor
unclear
recent
treatment
antimicrobi
like
signific
recent
therapi
repeat
cours
therapi
macrolid
fluoroquinolon
risk
factor
pneumococc
resist
class
antibiot
one
studi
found
use
either
macrolid
within
previou
month
predict
increas
likelihood
pneumococc
bacteremia
present
organ
would
penicillin
resist
studi
shown
repeat
use
fluoroquinolon
predict
increas
risk
infect
fluoroquinoloneresist
pneumococci
whether
risk
appli
equal
fluoroquinolon
concern
less
activ
antipneumococc
agent
levofloxacin
ciprofloxacin
activ
agent
moxifloxacin
gemifloxacin
uncertain
recommend
use
highli
activ
agent
patient
risk
infect
drsp
therefor
base
part
efficaci
consider
also
base
desir
prevent
resist
emerg
employ
potent
regimen
possibl
although
increas
dose
certain
agent
penicillin
cephalosporin
levofloxacin
may
lead
adequ
outcom
major
case
switch
potent
agent
may
lead
stabil
even
overal
decreas
resist
rate
camrsarec
increas
incid
pneumonia
due
camrsa
observ
camrsa
appear
pattern
typic
hospitalacquir
strain
recent
strain
epidemiolog
genotyp
phenotyp
distinct
hospitalacquir
strain
mani
former
may
repres
hcap
earlier
studi
differenti
group
typic
cap
latter
resist
fewer
antimicrobi
hospitalacquir
mrsa
strain
often
contain
novel
type
iv
sccmec
gene
addit
contain
gene
pantonvalentin
leukocidin
toxin
associ
clinic
featur
necrot
pneumonia
shock
respiratori
failur
well
format
abscess
empyema
larg
major
case
publish
date
skin
infect
children
larg
studi
camrsa
commun
camrsa
infect
pneumonia
howev
pneumonia
adult
children
report
often
associ
preced
influenza
strain
also
suspect
patient
present
cavitari
infiltr
without
risk
factor
anaerob
aspir
pneumonia
gingiv
risk
loss
conscious
seizur
alcohol
abus
esophog
motil
disord
diagnosi
usual
straightforward
high
yield
sputum
blood
cultur
characterist
clinic
scenario
camrsa
cap
remain
rare
commun
expect
emerg
problem
cap
treatment
outpati
treatmentth
follow
regimen
recommend
outpati
treatment
basi
list
clinic
risk
previous
healthi
risk
factor
drsp
infect
macrolid
azithromycin
clarithromycin
erythromycin
strong
recommend
level
evid
doxycyclin
weak
recommend
level
iii
evid
presenc
comorbid
chronic
heart
lung
liver
renal
diseas
diabet
mellitu
alcohol
malign
asplenia
immunosuppress
condit
use
immunosuppress
drug
use
antimicrobi
within
previou
month
case
altern
differ
class
select
risk
drsp
infect
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
strong
recommend
level
evid
plu
macrolid
strong
recommend
level
evid
highdos
amoxicillin
eg
g
time
daili
amoxicillinclavulan
g
time
daili
prefer
altern
includ
ceftriaxon
cefpodoxim
cefuroxim
mg
time
daili
doxycyclin
level
ii
evid
altern
macrolid
region
high
rate
infect
highlevel
mic
macrolideresist
pneumonia
consid
use
altern
agent
list
recommend
patient
includ
without
comorbid
moder
recommend
level
iii
evid
common
pathogen
identifi
recent
studi
mild
ambulatori
cap
pneumonia
pneumonia
c
pneumonia
h
influenza
mycoplasma
infect
common
among
patient
year
age
without
signific
comorbid
condit
abnorm
vital
sign
wherea
pneumonia
common
pathogen
among
older
patient
among
signific
underli
diseas
hemophilu
infect
found
patient
comorbid
import
therapi
mycoplasma
infect
chlamydophila
infect
mild
cap
subject
debat
mani
infect
selflimit
nevertheless
studi
children
indic
treatment
mild
pneumonia
cap
reduc
morbid
pneumonia
shorten
durat
symptom
evid
support
specif
treatment
microorgan
adult
lack
macrolid
long
commonli
prescrib
treatment
outpati
cap
unit
state
activ
pneumonia
atyp
pathogen
class
includ
erythromycintyp
agent
includ
dirithromycin
clarithromycin
azalid
azithromycin
although
least
expens
erythromycin
often
use
gastrointestin
intoler
lack
activ
h
influenza
h
influenza
azithromycin
prefer
outpati
comorbid
copd
numer
random
clinic
trial
document
efficaci
clarithromycin
azithromycin
monotherapi
outpati
cap
although
sever
studi
demonstr
clinic
failur
occur
resist
isol
patient
hospit
treat
macrolid
howev
surviv
gener
recov
without
signific
complic
patient
risk
factor
therapi
macrolid
alon
recommend
present
guidelin
thu
patient
signific
risk
drsp
infect
monotherapi
macrolid
recommend
doxycyclin
includ
costeffect
altern
basi
vitro
data
indic
effect
equival
erythromycin
pneumococc
isol
use
fluoroquinolon
treat
ambulatori
patient
cap
without
comorbid
condit
risk
factor
drsp
recent
antimicrobi
use
discourag
concern
widespread
use
may
lead
develop
fluoroquinolon
resist
howev
fraction
total
fluoroquinolon
use
specif
cap
extrem
small
unlik
lead
increas
resist
concern
recent
studi
suggest
mani
outpati
given
fluoroquinolon
may
even
requir
antibiot
dose
durat
treatment
often
incorrect
anoth
agent
often
use
firstlin
therapi
usag
pattern
may
promot
rapid
develop
resist
fluoroquinolon
comorbid
recent
antimicrobi
therapi
increas
likelihood
infect
drsp
enter
gramneg
bacteria
patient
recommend
empir
therapeut
option
includ
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
daili
combin
therapi
effect
pneumonia
plu
macrolid
doxycyclin
altern
basi
present
pharmacodynam
principl
highdos
amoxicillin
amoxicillin
g
time
daili
amoxicillinclavulan
g
time
daili
target
pneumonia
prefer
ceftriaxon
altern
highdos
amoxicillin
parenter
therapi
feasibl
select
oral
cephalosporin
cefpodoxim
cefuroxim
use
altern
less
activ
vitro
highdos
amoxicillin
ceftriaxon
agent
class
patient
receiv
previous
use
treat
patient
recent
antibiot
exposur
telithromycin
first
ketolid
antibiot
deriv
macrolid
famili
activ
pneumonia
resist
antimicrobi
commonli
use
cap
includ
penicillin
macrolid
fluoroquinolon
sever
cap
trial
suggest
telithromycin
equival
compar
includ
amoxicillin
clarithromycin
trovafloxacin
also
recent
postmarket
report
lifethreaten
hepatotox
present
committe
await
evalu
safeti
drug
fda
make
final
recommendationinpati
nonicu
treatmentth
follow
regimen
recommend
hospit
ward
treatment
respiratori
fluoroquinolon
strong
recommend
level
evid
plu
macrolid
strong
recommend
level
evid
prefer
agent
includ
cefotaxim
ceftriaxon
ampicillin
ertapenem
select
patient
doxycyclin
level
iii
evid
altern
macrolid
respiratori
fluoroquinolon
use
penicillinallerg
patient
recommend
combin
treatment
plu
macrolid
monotherapi
fluoroquinolon
base
retrospect
studi
demonstr
signific
reduct
mortal
compar
associ
administr
cephalosporin
alon
multipl
prospect
random
trial
demonstr
either
regimen
result
high
cure
rate
major
discrimin
factor
regimen
patient
prior
antibiot
exposur
within
past
month
prefer
effect
pneumonia
common
nonatyp
pathogen
without
overli
broad
spectrum
januari
clinic
laboratori
standard
institut
formerli
nccl
increas
mic
breakpoint
cefotaxim
ceftriaxon
nonmening
pneumonia
infect
new
breakpoint
acknowledg
nonmening
infect
caus
strain
formerli
consid
intermedi
suscept
even
resist
treat
success
usual
dose
two
random
doubleblind
studi
show
ertapenem
equival
ceftriaxon
also
excel
activ
anaerob
organ
drsp
enterobacteriacea
speci
includ
extendedspectrum
produc
p
aeruginosa
ertapenem
may
use
treat
patient
risk
infect
pathogen
patient
recent
receiv
antibiot
therapi
howev
clinic
experi
agent
limit
antipneumococc
antipseudomon
agent
appropri
resist
pathogen
pseudomona
like
present
doxycyclin
use
altern
macrolid
basi
scant
data
treatment
legionella
infect
two
random
doubleblind
studi
adult
hospit
cap
demonstr
parenter
azithromycin
alon
effect
improv
toler
intraven
cefuroxim
without
intraven
erythromycin
anoth
studi
mortal
readmiss
rate
similar
mean
lo
shorter
among
patient
receiv
azithromycin
alon
among
receiv
guidelinerecommend
therapi
none
patient
erythromycinresist
pneumonia
infect
die
transfer
icu
includ
receiv
azithromycin
alon
anoth
studi
show
receiv
macrolid
alon
lowest
mortal
least
ill
patient
younger
like
lowerrisk
group
studi
suggest
therapi
azithromycin
alon
consid
care
select
patient
cap
nonsever
diseas
patient
admit
primarili
reason
cap
risk
factor
infect
drsp
gramneg
pathogen
howev
emerg
high
rate
macrolid
resist
mani
area
countri
suggest
therapi
routin
recommend
initi
therapi
given
intraven
admit
patient
without
risk
factor
sever
pneumonia
could
receiv
oral
therapi
especi
highli
bioavail
agent
fluoroquinolon
intraven
combin
coverag
atyp
pathogen
oral
therapi
macrolid
doxycyclin
appropri
select
patient
without
sever
pneumonia
risk
factor
inpati
icu
treatmentth
follow
regimen
minim
recommend
treatment
patient
admit
icu
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
level
ii
evid
fluoroquinolon
level
evid
strong
recommend
penicillinallerg
patient
respiratori
fluoroquinolon
aztreonam
recommend
singl
random
control
trial
treatment
sever
cap
avail
patient
shock
exclud
howev
among
patient
mechan
ventil
treatment
fluoroquinolon
alon
result
trend
toward
inferior
outcom
septic
shock
mechan
ventil
clearest
reason
icu
admiss
major
icu
patient
would
still
requir
combin
therapi
icu
patient
routin
exclud
trial
therefor
recommend
extrapol
nonsever
case
conjunct
case
seri
retrospect
analys
cohort
sever
cap
patient
admit
icu
coverag
pneumonia
legionella
speci
ensur
use
potent
antipneumococc
either
macrolid
fluoroquinolon
therapi
respiratori
fluoroquinolon
alon
establish
sever
cap
patient
concomit
pneumococc
mening
efficaci
fluoroquinolon
monotherapi
uncertain
addit
prospect
observ
studi
retrospect
analys
found
combin
therapi
bacterem
pneumococc
pneumonia
associ
lower
mortal
monotherapi
mechan
benefit
unclear
princip
found
patient
sever
ill
demonstr
nonbacterem
pneumococc
cap
studi
therefor
combin
empir
therapi
recommend
least
h
result
diagnost
test
known
critic
ill
patient
cap
larg
number
microorgan
pneumonia
legionella
speci
must
consid
review
studi
includ
patient
cap
admit
icu
demonstr
common
pathogen
icu
popul
descend
order
frequenc
pneumonia
legionella
speci
h
influenza
enterobacteriacea
speci
aureu
pseudomona
speci
atyp
pathogen
respons
sever
cap
may
vari
time
account
collect
sever
pneumonia
episod
domin
atyp
pathogen
sever
cap
legionella
diagnost
bia
probabl
account
find
recommend
standard
empir
regimen
routin
cover
common
pathogen
caus
sever
cap
atyp
pathogen
relev
enterobacteriacea
speci
treatment
mrsa
p
aeruginosa
infect
main
reason
modifi
standard
empir
regimen
follow
addit
modif
basic
empir
regimen
recommend
pathogen
suspect
pseudomona
infect
use
antipneumococc
antipseudomon
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
dose
plu
aminoglycosid
azithromycin
plu
aminoglycosid
antipneumococc
fluoroquinolon
penicillinallerg
patient
substitut
aztreonam
moder
recommend
level
iii
evid
pseudomon
cap
requir
combin
treatment
prevent
inappropri
initi
therapi
pseudomona
nosocomi
pneumonia
suscept
known
treatment
adjust
accordingli
altern
regimen
provid
patient
may
recent
receiv
oral
fluoroquinolon
aminoglycosidecontain
regimen
would
prefer
consist
gram
stain
tracheal
aspir
sputum
blood
best
indic
pseudomona
coverag
easiertotreat
gramneg
microorgan
may
ultim
proven
caus
pathogen
empir
coverag
pseudomona
speci
cultur
result
known
least
like
associ
inappropri
therapi
clinic
risk
factor
infect
pseudomona
speci
includ
structur
lung
diseas
bronchiectasi
repeat
exacerb
sever
copd
lead
frequent
steroid
andor
antibiot
use
well
prior
antibiot
therapi
patient
necessarili
requir
icu
admiss
cap
pseudomona
infect
remain
concern
even
hospit
gener
ward
major
risk
factor
infect
seriou
gramneg
pathogen
klebsiella
pneumonia
acinetobact
speci
chronic
alcohol
camrsa
infect
add
vancomycin
linezolid
moder
recommend
level
iii
evid
best
indic
aureu
infect
presenc
gramposit
cocci
cluster
tracheal
aspir
adequ
sputum
sampl
find
preliminari
result
blood
cultur
reliabl
signific
risk
contamin
clinic
risk
factor
aureu
cap
includ
endstag
renal
diseas
inject
drug
abus
prior
influenza
prior
antibiot
therapi
especi
fluoroquinolon
methicillinsensit
aureu
empir
combin
therapi
recommend
includ
sometim
respiratori
fluoroquinolon
adequ
suscept
result
avail
specif
therapi
penicillinaseresist
semisynthet
penicillin
firstgener
cephalosporin
initi
also
offer
addit
coverag
drsp
neither
linezolid
vancomycin
optim
drug
methicillinsensit
aureu
although
methicillinresist
strain
aureu
still
minor
excess
mortal
associ
inappropri
antibiot
therapi
would
suggest
empir
coverag
consid
camrsa
concern
effect
therapi
yet
defin
major
camrsa
strain
suscept
vitro
antimicrobi
includ
trimethoprimsulfamethoxazol
tmpsmx
fluoroquinolon
hospitalacquir
strain
previou
experi
tmpsmx
type
sever
infect
endocard
septic
thrombophleb
suggest
tmpsmx
inferior
vancomycin
experi
studi
adequaci
tmpsmx
camrsa
cap
clearli
need
vancomycin
never
specif
studi
cap
linezolid
found
better
ceftriaxon
bacterem
pneumonia
nonblind
studi
superior
vancomycin
retrospect
analysi
studi
involv
nosocomi
mrsa
pneumonia
newer
agent
mrsa
recent
becom
avail
other
anticip
present
avail
agent
daptomycin
use
cap
data
pneumonia
avail
tigecyclin
concern
camrsa
necrot
pneumonia
associ
product
pantonvalentin
leukocidin
toxin
vancomycin
clearli
decreas
toxin
product
effect
tmpsmx
fluoroquinolon
toxin
product
unclear
addit
clindamycin
use
linezolid
shown
affect
toxin
product
laboratori
set
may
warrant
consider
treatment
necrot
pneumonia
unfortun
emerg
resist
therapi
clindamycin
report
especi
erythromycinresist
strain
vancomycin
would
still
need
bacteri
kill
clinician
awar
epidemiolog
condit
andor
risk
factor
may
suggest
altern
specif
addit
antibiot
consid
condit
specif
pathogen
prefer
treatment
list
tabl
etiolog
cap
identifi
basi
reliabl
microbiolog
method
antimicrobi
therapi
direct
pathogen
moder
recommend
level
iii
evid
treatment
option
may
simplifi
tabl
etiolog
agent
establish
strongli
suspect
diagnost
procedur
identifi
specif
etiolog
within
h
still
use
guid
continu
therapi
inform
often
avail
time
consider
switch
parenter
oral
therapi
may
use
direct
specif
oral
antimicrobi
choic
exampl
appropri
cultur
reveal
penicillinsuscept
pneumonia
narrowspectrum
agent
penicillin
amoxicillin
may
use
hope
reduc
select
pressur
resist
major
issu
pathogenspecif
therapi
manag
bacterem
pneumonia
cap
implic
observ
find
dual
therapi
associ
reduc
mortal
bacterem
pneumococc
pneumonia
uncertain
one
explan
reduc
mortal
may
presenc
undiagnos
coinfect
atyp
pathogen
although
report
occur
cap
case
studi
much
lower
rate
undiagnos
coinfect
found
gener
specif
sever
case
altern
explan
immunomodulatori
effect
macrolid
import
note
studi
evalu
effect
initi
empir
therapi
result
blood
cultur
known
examin
effect
pathogenspecif
therapi
result
blood
cultur
avail
benefit
combin
therapi
also
pronounc
sever
ill
patient
therefor
discontinu
combin
therapi
result
cultur
known
like
safe
nonicu
patient
earli
treatment
within
h
onset
symptom
oseltamivir
zanamivir
recommend
influenza
strong
recommend
level
evid
use
oseltamivir
zanamivir
recommend
patient
uncompl
influenza
symptom
h
level
evid
drug
may
use
reduc
viral
shed
hospit
patient
influenza
pneumonia
moder
recommend
level
iii
evid
studi
demonstr
treatment
influenza
effect
institut
within
h
onset
symptom
perform
uncompl
case
impact
treatment
patient
hospit
influenza
pneumonia
bacteri
pneumonia
complic
influenza
unclear
hospit
adult
influenza
minor
radiograph
document
pneumonia
obviou
benefit
found
one
retrospect
studi
amantadin
treatment
treatment
antigen
cultureposit
patient
influenza
antivir
addit
antibiot
warrant
even
radiograph
infiltr
caus
subsequ
bacteri
superinfect
longer
period
persist
posit
infect
appropri
treatment
patient
diagnos
rapid
diagnost
test
unclear
patient
often
recover
viru
median
durat
day
hospit
antivir
treatment
seem
reason
infectioncontrol
standpoint
alon
broad
influenza
spectrum
low
risk
resist
emerg
lack
bronchospasm
risk
oseltamivir
appropri
choic
hospit
patient
neuraminidas
inhibitor
effect
influenza
b
virus
wherea
inhibitor
amantadin
rimantadin
activ
influenza
addit
virus
recent
circul
unit
state
canada
often
resist
inhibitor
basi
antivir
test
therefor
neither
amantadin
rimantadin
use
treatment
chemoprophylaxi
influenza
unit
state
suscept
antivir
medic
reestablish
among
circul
influenza
virus
earli
treatment
influenza
ambulatori
adult
inhal
zanamivir
oral
oseltamivir
appear
reduc
likelihood
lower
respiratori
tract
complic
use
influenza
antivir
medic
appear
reduc
likelihood
respiratori
tract
complic
reflect
reduc
usag
rate
antibacteri
agent
ambulatori
patient
influenza
although
clearli
import
outpati
pneumonia
experi
may
also
appli
patient
hospit
primarili
influenza
parenter
acyclovir
indic
treatment
varicellazost
viru
infect
herp
simplex
viru
pneumonia
antivir
treatment
proven
valu
avail
viral
parainfluenza
viru
rsv
adenoviru
metapneumoviru
sar
agent
hantaviru
patient
viral
pneumonia
high
clinic
suspicion
bacteri
superinfect
maintainedpandem
influenza
patient
ill
compat
influenza
known
exposur
poultri
area
previou
infect
test
infect
moder
recommend
level
iii
evid
patient
suspect
infect
droplet
precaut
care
routin
infect
control
measur
use
infect
rule
moder
recommend
level
iii
evid
patient
suspect
infect
treat
oseltamivir
level
ii
evid
antibacteri
agent
target
pneumonia
aureu
common
caus
secondari
bacteri
pneumonia
patient
influenza
level
iii
evid
moder
recommend
recent
human
infect
caus
avian
influenza
vietnam
thailand
cambodia
china
indonesia
egypt
turkey
rais
possibl
pandem
near
futur
sever
infect
human
distinguish
caus
routin
season
influenza
respiratori
failur
requir
hospit
intens
care
seen
major
recogn
case
mortal
pandem
occur
death
result
primari
influenza
pneumonia
without
secondari
bacteri
pneumonia
section
highlight
issu
consider
recogn
treatment
recommend
like
chang
pandem
progress
specif
guidanc
found
idsa
at
cdc
web
site
key
featur
pandem
becom
clearer
addit
guidanc
avail
http
wwwpandemicflugov
delin
phase
influenza
pandem
defin
increas
level
risk
public
health
respons
current
pandem
alert
phase
phase
case
novel
influenza
infect
without
sustain
persontoperson
transmiss
test
focus
confirm
suspect
case
area
infect
document
poultri
detect
arriv
pandem
strain
unaffect
countri
earli
clinic
featur
infect
includ
persist
fever
cough
respiratori
difficulti
progress
day
well
lymphopenia
admiss
hospit
exposur
sick
die
poultri
area
known
suspect
activ
report
patient
although
recognit
poultri
outbreak
sometim
follow
recognit
human
case
rapid
bedsid
test
detect
influenza
use
screen
tool
avian
influenza
set
throat
swab
test
rtpcr
sensit
confirm
infect
date
nasopharyng
swab
wash
aspir
bal
fluid
lung
tissu
stool
yield
posit
result
rtpcr
viral
cultur
vari
sensit
convalescentphas
serum
test
microneutr
antibodi
antigen
small
number
intern
refer
laboratori
specimen
suspect
case
infect
sent
public
health
laboratori
appropri
biocontain
facil
case
discuss
health
depart
offici
arrang
transfer
specimen
initi
epidemiolog
evalu
later
phase
ongo
pandem
test
may
necessari
mani
patient
appropri
treatment
infect
control
decis
made
assist
defin
extent
pandem
recommend
test
evolv
basi
featur
pandem
guidanc
sought
cdc
web
site
http
wwwcdcgov
http
wwwwhoint
patient
confirm
suspect
influenza
treat
oseltamivir
isol
sinc
suscept
neuraminidas
inhibitor
oseltamivir
zanamivir
resist
adamantan
amantidin
rimantidin
current
recommend
cours
treatment
standard
dosag
mg
time
daili
addit
droplet
precaut
use
patient
suspect
influenza
place
respiratori
isol
etiolog
rule
health
care
personnel
wear
higher
respir
medic
procedur
high
likelihood
gener
infecti
respiratori
aerosol
bacteri
superinfect
particularli
pneumonia
import
complic
influenza
pneumonia
bacteri
etiolog
cap
influenza
infect
includ
pneumonia
aureu
h
influenza
group
streptococci
legionella
chlamydophila
mycoplasma
speci
import
caus
secondari
bacteri
pneumonia
influenza
appropri
agent
would
therefor
includ
cefotaxim
ceftriaxon
respiratori
fluoroquinolon
treatment
vancomycin
linezolid
agent
direct
camrsa
limit
patient
confirm
infect
compat
clinic
present
shock
necrot
pneumonia
shortag
antibacteri
antivir
anticip
pandem
appropri
use
diagnost
test
even
import
help
target
antibacteri
therapi
whenev
possibl
especi
patient
admit
hospit
patient
admit
ed
first
antibiot
dose
administ
still
ed
moder
recommend
level
iii
evid
time
first
antibiot
dose
cap
recent
receiv
signific
attent
qualityofcar
perspect
emphasi
base
retrospect
studi
medicar
beneficiari
demonstr
statist
significantli
lower
mortal
among
patient
receiv
earli
antibiot
therapi
initi
studi
suggest
breakpoint
h
wherea
subsequ
analysi
found
h
associ
lower
mortal
studi
document
time
first
antibiot
dose
consist
demonstr
differ
although
none
larg
patient
popul
importantli
prospect
trial
care
protocol
demonstr
surviv
benefit
increas
percentag
patient
cap
receiv
antibiot
within
first
h
earli
antibiot
administr
appear
shorten
time
clinic
stabil
either
although
time
first
dose
appear
correl
lo
problem
intern
consist
also
present
studi
patient
receiv
antibiot
first
h
present
actual
wors
receiv
antibiot
h
present
reason
committe
feel
specif
time
window
deliveri
first
antibiot
dose
recommend
howev
committe
feel
therapi
administ
soon
possibl
diagnosi
consid
like
convers
delay
antibiot
therapi
advers
consequ
mani
infect
critic
ill
hemodynam
unstabl
patient
earli
antibiot
therapi
encourag
although
prospect
data
support
recommend
delay
begin
antibiot
treatment
transit
ed
uncommon
especi
frequent
use
oncedaili
antibiot
cap
time
commun
issu
may
result
patient
receiv
antibiot
h
hospit
admiss
committe
felt
best
practic
resolut
issu
initi
dose
given
ed
data
medicar
databas
indic
antibiot
treatment
hospit
admiss
also
associ
lower
mortal
given
even
concern
regard
time
first
dose
antibiot
patient
directli
admit
busi
inpati
unit
provis
first
dose
physician
offic
may
best
recommend
oral
intramuscular
antibiot
avail
offic
patient
switch
intraven
oral
therapi
hemodynam
stabl
improv
clinic
abl
ingest
medic
normal
function
gastrointestin
tract
strong
recommend
level
ii
evid
patient
discharg
soon
clinic
stabl
activ
medic
problem
safe
environ
continu
care
inpati
observ
receiv
oral
therapi
necessari
moder
recommend
level
ii
evid
use
potent
highli
bioavail
antibiot
abil
eat
drink
major
consider
switch
intraven
oral
antibiot
therapi
nonicu
patient
initi
ramirez
et
al
defin
set
criteria
earli
switch
intraven
oral
therapi
tabl
gener
mani
twothird
patient
clinic
improv
meet
criteria
therapi
switch
first
day
nonicu
patient
meet
criteria
day
subsequ
studi
suggest
even
liber
criteria
adequ
switch
oral
therapi
altern
approach
chang
intraven
oral
therapi
predetermin
time
regardless
clinic
respons
one
studi
popul
nonsever
ill
random
receiv
either
oral
therapi
alon
intraven
therapi
switch
occur
h
without
fever
studi
popul
sever
ill
random
receiv
either
intraven
therapi
switch
oral
therapi
day
full
cours
intraven
antibiot
time
resolut
symptom
patient
nonsever
ill
similar
either
regimen
among
patient
sever
ill
rapid
switch
oral
therapi
rate
treatment
failur
time
resolut
symptom
prolong
intraven
therapi
rapidswitch
group
requir
fewer
inpati
day
vs
although
like
partial
result
protocol
patient
also
fewer
advers
event
need
keep
patient
hospit
clinic
stabil
achiev
question
even
though
physician
commonli
choos
observ
patient
receiv
oral
therapi
day
even
presenc
pneumococc
bacteremia
switch
oral
therapi
safe
done
clinic
stabil
achiev
prolong
intraven
therapi
need
patient
gener
take
longer
approxim
half
day
becom
clinic
stabl
nonbacterem
patient
benefit
inhospit
observ
switch
oral
therapi
limit
add
cost
care
discharg
consid
patient
candid
oral
therapi
need
treat
comorbid
ill
need
diagnost
test
unmet
social
need
although
clear
clinic
stabl
patient
safe
switch
oral
therapi
discharg
need
wait
featur
clinic
stabil
present
patient
discharg
uncertain
exampl
investig
found
necessari
white
blood
cell
count
improv
use
definit
clinic
stabil
tabl
halm
et
al
found
patient
discharg
hospit
instabl
death
readmiss
occur
patient
instabl
discharg
patient
instabl
instabl
gener
patient
higher
psi
class
take
longer
reach
clinic
stabil
patient
lower
risk
class
find
may
reflect
fact
elderli
patient
multipl
comorbid
often
recov
slowli
arrang
appropri
followup
care
includ
rehabilit
therefor
initi
earli
patient
gener
switch
oral
antibiot
either
agent
intraven
antibiot
drug
class
use
switch
differ
class
agent
simpli
high
bioavail
fluoroquinolon
probabl
necessari
respond
patient
patient
receiv
intraven
combin
therapi
switch
macrolid
alon
appear
safe
drsp
gramneg
enter
pathogen
isol
patient
cap
treat
minimum
day
level
evid
afebril
h
capassoci
sign
clinic
instabl
tabl
discontinu
therapi
level
ii
evid
moder
recommend
longer
durat
therapi
may
need
initi
therapi
activ
identifi
pathogen
complic
extrapulmonari
infect
mening
endocard
weak
recommend
level
iii
evid
patient
cap
treat
day
longer
wellcontrol
studi
evalu
optim
durat
therapi
patient
cap
manag
hospit
avail
data
shortcours
treatment
suggest
differ
outcom
appropri
therapi
either
inpati
outpati
durat
also
difficult
defin
uniform
fashion
antibiot
azithromycin
administ
short
time
yet
long
halflif
respiratori
site
infect
trial
antibiot
therapi
cap
azithromycin
use
day
oral
therapi
outpati
report
singledos
therapi
patient
atyp
pathogen
infect
result
azithromycin
extrapol
drug
significantli
shorter
halfliv
ketolid
telithromycin
use
day
treat
outpati
includ
pneumococc
bacteremia
psi
class
recent
studi
highdos
mg
levofloxacin
therapi
day
equal
success
result
afebril
patient
day
dose
day
vs
p
basi
studi
day
appear
minim
overal
durat
therapi
document
effect
usual
form
cap
discuss
patient
becom
clinic
stabl
within
day
longer
durat
therapi
rare
necessari
patient
persist
clinic
instabl
often
readmit
hospit
may
candid
shortdur
therapi
shortdur
therapi
may
suboptim
patient
bacterem
aureu
pneumonia
risk
associ
endocard
deepseat
infect
mening
endocard
complic
pneumonia
infect
less
common
pathogen
eg
burkholderia
pseudomallei
endem
fungi
cours
therapi
nosocomi
p
aeruginosa
pneumonia
led
relaps
commonli
cours
therapi
whether
result
would
applic
cap
case
unclear
presenc
caviti
sign
tissu
necrosi
may
warrant
prolong
treatment
studi
durat
therapi
focus
patient
receiv
empir
treatment
reliabl
data
defin
treatment
durat
initi
ineffect
regimen
lack
patient
cap
persist
septic
shock
despit
adequ
fluid
resuscit
consid
treatment
drotrecogin
alfa
activ
within
h
admiss
weak
recommend
level
ii
evid
drotrecogin
alfa
activ
first
immunomodulatori
therapi
approv
sever
sepsi
unit
state
fda
recommend
use
drotrecogin
alfa
activ
patient
high
risk
death
highrisk
criterion
suggest
fda
acut
physiolog
chronic
health
assess
apach
ii
score
base
subgroup
analysi
overal
studi
howev
surviv
advantag
absolut
risk
reduct
drotrecogin
alfa
activ
treatment
patient
cap
subgroup
equival
subgroup
apach
ii
score
greatest
reduct
mortal
rate
pneumonia
infect
rel
risk
ci
subsequ
data
suggest
benefit
appear
greatest
treatment
given
earli
hospit
admiss
possibl
subgroup
sever
cap
caus
pathogen
pneumonia
treat
appropri
antibiot
evid
drotrecogin
alfa
activ
affect
mortal
although
benefit
drotrecogin
alfa
activ
clearli
greatest
patient
cap
high
apach
ii
score
criterion
alon
may
adequ
select
appropri
patient
apach
ii
score
select
subgroup
analysi
entir
studi
cohort
may
similarli
calibr
caponli
cohort
twoorgan
failur
criterion
suggest
drotrecogin
alfa
activ
use
european
regulatori
agenc
influenc
mortal
benefit
patient
cap
therefor
addit
patient
septic
shock
patient
sever
cap
could
consid
treatment
drotrecogin
alfa
activ
sepsisinduc
leukopenia
extrem
high
risk
death
ard
therefor
potenti
candid
convers
benefit
drotrecogin
alfa
activ
clear
respiratori
failur
caus
exacerb
underli
lung
diseas
rather
pneumonia
minor
criteria
sever
cap
propos
similar
organ
failur
criteria
use
mani
sepsi
trial
consider
treatment
drotrecogin
alfa
activ
appropri
strength
recommend
level
ii
hypotens
fluidresuscit
patient
sever
cap
screen
occult
adren
insuffici
moder
recommend
level
ii
evid
larg
multicent
trial
suggest
stressdos
mg
hydrocortison
per
day
equival
steroid
treatment
improv
outcom
vasopressordepend
patient
septic
shock
appropri
cortisol
respons
stimul
patient
cap
made
signific
fraction
patient
enter
trial
addit
small
pilot
studi
suggest
benefit
corticosteroid
therapi
even
patient
sever
cap
shock
small
sampl
size
baselin
differ
group
compromis
conclus
although
criteria
steroid
replac
therapi
remain
controversi
frequenc
intermitt
steroid
treatment
patient
risk
sever
cap
sever
copd
suggest
screen
patient
sever
cap
appropri
replac
inadequ
cortisol
level
document
corticosteroid
use
close
attent
tight
glucos
control
requir
patient
hypoxemia
respiratori
distress
receiv
cautiou
trial
noninvas
ventil
niv
unless
requir
immedi
intub
sever
hypoxemia
arteri
oxygen
pressurefract
inspir
oxygen
ratio
bilater
alveolar
infiltr
moder
recommend
level
evid
patient
requir
immedi
intub
either
hypoxemia
respiratori
distress
receiv
trial
niv
patient
underli
copd
like
benefit
patient
cap
random
receiv
niv
absolut
risk
reduct
need
intub
use
niv
may
also
improv
intermediateterm
mortal
inabl
expector
may
limit
use
niv
intermitt
applic
niv
may
allow
use
patient
product
cough
unless
sputum
product
excess
prompt
recognit
fail
niv
trial
critic
import
studi
demonstr
wors
outcom
patient
requir
intub
prolong
niv
trial
within
first
h
niv
failur
improv
respiratori
rate
oxygen
failur
decreas
carbon
dioxid
partial
pressur
patient
initi
hypercarbia
predict
niv
failur
warrant
prompt
intub
niv
provid
benefit
patient
ard
may
nearli
indistinguish
cap
among
patient
bilater
alveolar
infiltr
patient
cap
sever
hypoxemia
ratio
also
poor
candid
niv
lowtidalvolum
ventil
ideal
bodi
weight
use
patient
undergo
ventil
diffus
bilater
pneumonia
ard
strong
recommend
level
evid
distinguish
diffus
bilater
pneumonia
ard
difficult
may
import
distinct
result
ardsnet
trial
suggest
use
lowtidalvolum
ventil
provid
surviv
advantag
pneumonia
princip
cap
common
caus
ard
trial
benefit
lowtidalvolum
ventilatori
strategi
appear
equival
popul
pneumonia
compar
entir
cohort
absolut
risk
reduct
mortal
pneumonia
cohort
indic
order
avoid
death
patient
must
treat
aspect
manag
sever
sepsi
septic
shock
patient
cap
appear
significantli
differ
patient
sourc
infect
recommend
aspect
care
review
elsewher
limit
diagnost
test
major
cap
still
treat
empir
critic
empir
therapi
understand
manag
patient
follow
normal
respons
pattern
although
difficult
defin
nonrespons
uncommon
overal
hospit
patient
cap
respond
initi
antibiot
treatment
incid
treatment
failur
among
patient
cap
hospit
well
known
populationbas
studi
requir
almiral
et
al
describ
overal
hospit
rate
populationbas
studi
rate
failur
among
patient
initi
present
primari
care
physician
provid
frequenc
prior
antibiot
therapi
among
medicar
patient
admit
hospit
cap
percentag
receiv
prior
antibiot
therapi
acut
episod
pneumonia
versu
indic
unclear
patient
initi
admit
icu
risk
failur
respond
alreadi
high
mani
experi
deterior
even
initi
stabil
icu
mortal
among
nonrespond
patient
increas
severalfold
comparison
among
respond
patient
overal
mortal
rate
high
report
entir
popul
nonrespond
hospit
patient
cap
mortal
rate
report
one
studi
earli
failur
apach
ii
score
factor
independ
associ
mortal
nonrespond
group
suggest
excess
mortal
may
due
factor
sever
ill
present
definit
classif
use
systemat
classif
possibl
caus
failur
respond
base
time
onset
type
failur
tabl
recommend
moder
recommend
level
ii
evid
term
nonrespond
pneumonia
use
defin
situat
inadequ
clinic
respons
present
despit
antibiot
treatment
lack
clearcut
valid
definit
literatur
make
nonrespons
difficult
studi
lack
respons
also
vari
accord
site
treatment
lack
respons
outpati
differ
patient
admit
icu
time
evalu
also
import
persist
fever
first
day
treatment
differ
significantli
fever
persist
recur
day
treatment
tabl
provid
construct
evalu
nonrespons
antibiot
treatment
cap
base
sever
studi
address
issu
two
pattern
unaccept
respons
seen
hospit
patient
first
progress
pneumonia
actual
clinic
deterior
acut
respiratori
failur
requir
ventilatori
support
andor
septic
shock
usual
occur
within
first
h
hospit
admiss
note
mani
patient
cap
ultim
requir
icu
admiss
initi
admit
nonicu
set
transfer
deterior
deterior
develop
respiratori
failur
hypotens
h
initi
treatment
often
relat
intercurr
complic
deterior
underli
diseas
develop
nosocomi
superinfect
second
pattern
persist
nonrespond
pneumonia
nonrespons
defin
absenc
delay
achiev
clinic
stabil
use
criteria
tabl
criteria
use
median
time
achiev
clinic
stabil
day
patient
quarter
patient
took
day
meet
criteria
stabil
stricter
definit
criteria
higher
psi
score
associ
longer
time
achiev
clinic
stabil
convers
subsequ
transfer
icu
achiev
degre
clinic
stabil
occur
case
separ
multicent
trial
demonstr
similar
find
given
result
concern
regard
nonrespons
temper
h
therapi
antibiot
chang
period
consid
patient
deterior
new
cultur
data
epidemiolog
clue
suggest
altern
etiolog
final
nonresolv
slowresolv
pneumonia
use
refer
condit
patient
present
persist
pulmonari
infiltr
day
initi
pneumonialik
syndrom
mani
patient
found
diseas
cap
care
evalu
two
studi
evalu
risk
factor
lack
respons
multivari
analys
includ
amen
medic
intervent
use
fluoroquinolon
independ
associ
better
respons
one
studi
wherea
discord
antimicrobi
therapi
associ
earli
failur
tabl
differ
risk
protect
factor
respect
odd
ratio
summar
specif
caus
may
respons
lack
respons
cap
classifi
arancibia
et
al
tabl
classif
may
use
clinician
systemat
approach
diagnos
potenti
caus
nonrespons
cap
although
origin
studi
case
could
classifi
subsequ
prospect
multicent
trial
found
caus
failur
could
determin
manag
nonrespond
capnonrespons
antibiot
cap
gener
result
clinic
respons
transfer
patient
higher
level
care
diagnost
test
escal
chang
treatment
issu
regard
hospit
admiss
icu
transfer
discuss
inadequ
host
respons
rather
inappropri
antibiot
therapi
unexpect
microorgan
common
caus
appar
antibiot
failur
guidelinerecommend
therapi
use
decis
regard
diagnost
test
antibiot
changeescal
intim
intertwin
need
discuss
tandem
inform
regard
util
extens
microbiolog
test
case
nonrespond
cap
mainli
retrospect
therefor
affect
select
bia
systemat
diagnost
approach
includ
invas
noninvas
imag
procedur
seri
nonrespond
patient
cap
obtain
specif
diagnosi
differ
studi
mortal
among
patient
microbiolog
guid
versu
empir
antibiot
chang
improv
mortal
rate
vs
respect
howev
antibiot
chang
base
sole
sputum
smear
suggest
invas
cultur
noncultur
method
may
need
mismatch
suscept
common
caus
organ
infect
pathogen
cover
usual
empir
regimen
nosocomi
superinfect
pneumonia
major
caus
appar
antibiot
failur
therefor
first
respons
nonrespons
deterior
reevalu
initi
microbiolog
result
cultur
sensit
data
avail
admiss
may
make
caus
clinic
failur
obviou
addit
histori
risk
factor
infect
unusu
microorgan
tabl
taken
done
previous
virus
rel
neglect
caus
infect
adult
may
account
case
famili
member
cowork
may
develop
viral
symptom
interv
sinc
patient
admit
increas
suspicion
caus
evalu
nonrespons
sever
hamper
microbiolog
diagnosi
made
initi
present
cultur
obtain
clinic
decis
much
difficult
adequ
cultur
obtain
neg
risk
factor
nonrespons
deterior
tabl
therefor
figur
promin
list
situat
aggress
initi
diagnost
test
warrant
tabl
blood
cultur
repeat
deterior
progress
pneumonia
deterior
patient
mani
risk
factor
bacteremia
blood
cultur
still
high
yield
even
face
prior
antibiot
therapi
posit
blood
cultur
result
face
adequ
antibiot
therapi
increas
suspicion
either
antibioticresist
isol
metastat
site
endocard
arthriti
despit
high
frequenc
infecti
pulmonari
caus
nonrespons
diagnost
util
respiratori
tract
cultur
less
clear
caution
interpret
sputum
tracheal
aspir
cultur
especi
gramneg
bacilli
warrant
earli
colon
rather
superinfect
resist
bacteria
uncommon
specimen
obtain
initi
antibiot
treatment
absenc
multidrugresist
pathogen
mrsa
pseudomona
strong
evid
caus
nonrespons
etiolog
determin
bronchoscopi
patient
cap
mainli
respond
therapi
despit
potenti
benefit
suggest
result
contrast
ventilatorassoci
pneumonia
random
studi
compar
util
invas
versu
noninvas
strategi
cap
popul
nonrespons
rapid
urinari
antigen
test
pneumonia
l
pneumophila
remain
posit
day
initi
antibiot
therapi
therefor
may
highyield
test
group
urinari
antigen
test
result
posit
l
pneumophila
sever
clinic
implic
includ
coverag
legionella
ad
start
empir
find
may
partial
explan
find
fluoroquinolon
associ
lower
incid
nonrespons
patient
persist
fever
faster
respons
fluoroquinolon
legionella
cap
warrant
consider
switch
coverag
macrolid
stop
compon
combin
therapi
exclud
drug
fever
probabl
also
safe
one
major
explan
nonrespons
poor
host
immun
rather
incorrect
antibiot
posit
pneumococc
antigen
test
result
would
least
clarifi
probabl
origin
pathogen
turn
attent
caus
failur
addit
posit
pneumococc
antigen
test
result
would
also
help
interpret
subsequ
sputumtrach
aspir
cultur
may
indic
earli
superinfect
nonrespons
may
also
mimick
concomit
subsequ
extrapulmonari
infect
intravascular
cathet
urinari
abdomin
skin
infect
particularli
icu
patient
appropri
cultur
site
consid
patient
nonrespons
cap
therapi
addit
microbiolog
diagnost
procedur
sever
test
appear
valuabl
select
patient
nonrespons
chest
ct
addit
rule
pulmonari
emboli
ct
scan
disclos
reason
antibiot
failur
includ
pleural
effus
lung
abscess
central
airway
obstruct
pattern
opac
may
also
suggest
altern
noninfecti
diseas
bronchiol
obliteran
organ
pneumonia
thoracentesi
empyema
parapneumon
effus
import
caus
nonrespons
thoracentesi
perform
whenev
signific
pleural
fluid
present
bronchoscopi
bal
transbronchi
biopsi
differenti
nonrespons
includ
noninfecti
pneumonia
mimic
bronchoscopi
provid
diagnost
inform
routin
microbiolog
cultur
bal
may
reveal
noninfecti
entiti
pulmonari
hemorrhag
acut
eosinophil
pneumonia
hint
infecti
diseas
lymphocyt
rather
neutrophil
alveol
point
toward
viru
chlamydophila
infect
transbronchi
biopsi
also
yield
specif
diagnosi
antibiot
manag
nonrespons
cap
studi
overwhelm
major
case
appar
nonrespons
due
sever
ill
present
delay
treatment
respons
relat
host
factor
use
combin
therapi
sever
bacterem
pneumococc
pneumonia
document
addit
antibiot
earli
deterior
lead
better
outcom
presenc
risk
factor
potenti
untreat
microorgan
may
warrant
temporari
empir
broaden
antibiot
regimen
result
diagnost
test
avail
person
year
age
other
risk
influenza
complic
household
contact
highrisk
person
health
care
worker
receiv
inactiv
influenza
vaccin
recommend
advisori
committe
immun
practic
acip
cdc
strong
recommend
level
evid
intranas
administ
live
attenu
vaccin
altern
vaccin
formul
person
year
age
without
chronic
underli
diseas
includ
immunodefici
asthma
chronic
medic
condit
strong
recommend
level
evid
health
care
worker
inpati
outpati
set
longterm
care
facil
receiv
annual
influenza
immun
strong
recommend
level
evid
pneumococc
polysaccharid
vaccin
recommend
person
year
age
select
highrisk
concurr
diseas
accord
current
acip
guidelin
strong
recommend
level
ii
evid
vaccin
target
pneumococc
diseas
influenza
remain
mainstay
prevent
cap
pneumococc
polysaccharid
vaccin
inactiv
influenza
vaccin
recommend
older
adult
younger
person
medic
condit
place
high
risk
pneumonia
morbid
mortal
tabl
new
live
attenu
influenza
vaccin
recommend
healthi
person
year
age
includ
health
care
worker
postlicensur
epidemiolog
studi
document
effect
pneumococc
polysaccharid
vaccin
prevent
invas
infect
bacteremia
mening
among
elderli
individu
younger
adult
certain
chronic
medic
condit
overal
effect
invas
pneumococc
diseas
among
person
year
age
although
efficaci
may
decreas
advanc
age
effect
vaccin
pneumococc
diseas
immunocompromis
person
less
clear
result
studi
evalu
effect
pneumonia
without
bacteremia
mix
vaccin
shown
cost
effect
gener
popul
adult
year
age
year
age
second
dose
pneumococc
polysaccharid
vaccin
interv
shown
safe
slightli
local
reaction
seen
first
dose
safeti
third
dose
demonstr
current
guidelin
suggest
repeat
revaccin
pneumococc
conjug
vaccin
investig
use
adult
current
licens
use
young
children
howev
use
children
year
age
dramat
reduc
invas
pneumococc
bacteremia
among
adult
well
effect
influenza
vaccin
depend
host
factor
close
antigen
vaccin
match
circul
strain
influenza
systemat
review
demonstr
influenza
vaccin
effect
prevent
pneumonia
hospit
death
recent
larg
observ
studi
adult
year
age
found
vaccin
influenza
associ
reduct
risk
hospit
cardiac
diseas
reduct
cerebrovascular
diseas
reduct
pneumonia
influenza
reduct
reduct
risk
death
caus
reduct
longtermcar
facil
vaccin
health
care
worker
influenza
vaccin
import
prevent
health
measur
main
virul
factor
influenza
viru
neuraminidas
hemagglutinin
adapt
quickli
select
pressur
new
vaccin
formul
creat
year
basi
strain
expect
circul
annual
revaccin
need
optim
protect
vaccin
statu
assess
time
hospit
admiss
patient
especi
medic
ill
moder
recommend
level
iii
evid
vaccin
may
perform
either
hospit
discharg
outpati
treatment
moder
recommend
level
iii
evid
influenza
vaccin
offer
person
hospit
discharg
outpati
treatment
fall
winter
strong
recommend
level
iii
evid
mani
peopl
receiv
either
influenza
pneumococc
polysaccharid
vaccin
receiv
accord
survey
adult
year
age
receiv
influenza
vaccin
past
year
ever
receiv
pneumococc
polysaccharid
vaccin
coverag
level
lower
younger
person
vaccin
indic
among
adult
year
age
diabet
receiv
influenza
vaccin
ever
receiv
pneumococc
vaccin
studi
vaccin
deliveri
method
indic
use
stand
order
best
way
improv
vaccin
coverag
offic
hospit
longterm
care
set
hospit
atrisk
patient
repres
underutil
opportun
assess
vaccin
statu
either
provid
recommend
immun
ideal
patient
vaccin
develop
pneumonia
therefor
admiss
ill
respiratori
tract
infect
would
appropri
focu
howev
admiss
pneumonia
import
trigger
assess
need
immun
actual
immun
may
better
provid
time
outpati
followup
especi
emphasi
earli
discharg
patient
cap
patient
acut
fever
vaccin
fever
resolv
confus
febril
reaction
immun
recurrentsuperinfect
pneumonia
risk
howev
immun
discharg
pneumonia
warrant
patient
outpati
followup
unreli
vaccin
safe
given
mani
patient
best
time
influenza
vaccin
north
america
octob
novemb
although
vaccin
decemb
later
recommend
vaccin
earlier
influenza
pneumococc
vaccin
given
time
differ
arm
chemoprophylaxi
use
adjunct
vaccin
prevent
control
influenza
oseltamivir
zanamivir
approv
prophylaxi
amantadin
rimantadin
fda
indic
chemoprophylaxi
influenza
infect
agent
current
recommend
frequenc
resist
among
strain
circul
unit
state
canada
develop
adequ
immun
respons
inactiv
influenza
vaccin
take
week
adult
chemoprophylaxi
may
use
period
household
exposur
influenza
live
work
institut
influenza
outbreak
high
risk
influenza
complic
set
commun
outbreak
chemoprophylaxi
also
may
use
person
contraind
influenza
vaccin
adjunct
vaccin
may
respond
well
influenza
vaccin
eg
person
hiv
infect
use
influenza
antivir
medic
treatment
chemoprophylaxi
affect
respons
inactiv
vaccin
unknown
whether
administ
influenza
antivir
medic
affect
perform
new
live
attenu
intranas
vaccin
vaccin
use
conjunct
antivir
agent
type
vaccin
consid
pertussi
rare
caus
pneumonia
howev
pneumonia
one
major
complic
pertussi
concern
wane
immun
led
acip
emphas
adult
immun
pertussi
onetim
vaccin
new
tetanu
toxoid
reduc
diphtheria
toxoid
acellular
pertussi
tdap
product
adacel
sanofi
pasteur
recommend
adult
year
age
adult
vaccin
given
place
next
routin
tetanusdiphtheria
booster
adult
close
contact
infant
month
age
health
care
worker
receiv
vaccin
soon
possibl
interv
short
year
recent
tetanusdiphtheria
booster
smoke
cessat
goal
person
hospit
cap
smoke
moder
recommend
level
iii
evid
smoker
quit
also
vaccin
pneumococcu
influenza
weak
recommend
level
iii
evid
smoke
associ
substanti
risk
pneumococc
bacteremia
one
report
show
smoke
strongest
multipl
risk
invas
pneumococc
diseas
immunocompet
nonelderli
adult
smoke
also
identifi
risk
legionella
infect
smoke
cessat
attempt
smoker
hospit
particularli
import
relev
patient
hospit
pneumonia
materi
clinician
patient
assist
smoke
cessat
avail
onlin
us
surgeon
gener
http
wwwsurgeongeneralgovtobacco
center
diseas
control
prevent
http
wwwcdcgovtobacco
american
cancer
societi
http
wwwcancerorg
success
approach
quit
includ
combin
nicotin
replac
andor
bupropion
method
chang
habit
emot
support
given
increas
risk
pneumonia
committe
felt
person
unwil
stop
smoke
given
pneumococc
polysaccharid
vaccin
although
current
aciprecommend
indic
case
pneumonia
public
health
concern
report
immedi
state
local
health
depart
strong
recommend
level
iii
evid
public
health
intervent
import
prevent
form
pneumonia
notifi
state
local
health
depart
condit
interest
first
step
get
public
health
profession
involv
rule
regul
regard
diseas
report
differ
state
pneumonia
state
requir
report
legionnair
diseas
sar
psittacosi
investig
determin
whether
other
may
risk
whether
control
measur
necessari
legionnair
diseas
report
case
help
identifi
commonsourc
outbreak
caus
environment
contamin
sar
close
observ
case
quarantin
close
contact
critic
control
transmiss
addit
time
avian
influenza
possibl
terror
agent
eg
plagu
tularemia
anthrax
consid
etiolog
pneumonia
case
report
immedi
even
definit
diagnosi
obtain
addit
pneumonia
case
caus
pathogen
thought
endem
area
report
even
condit
typic
list
report
condit
control
strategi
might
possibl
respiratori
diseas
episod
suspect
part
outbreak
cluster
report
pneumococc
diseas
influenza
outbreak
occur
crowd
set
suscept
host
homeless
shelter
nurs
home
jail
set
prophylaxi
vaccin
infect
control
method
use
control
transmiss
mycoplasma
antibiot
prophylaxi
use
school
institut
control
outbreak
respiratori
hygien
measur
includ
use
hand
hygien
mask
tissu
patient
cough
use
outpati
set
ed
mean
reduc
spread
respiratori
infect
strong
recommend
level
iii
evid
part
emerg
sar
improv
respiratori
hygien
measur
respiratori
hygien
cough
etiquett
promot
mean
reduc
transmiss
respiratori
infect
outpati
clinic
ed
key
compon
respiratori
hygien
includ
encourag
patient
alert
provid
present
visit
symptom
respiratori
infect
use
hand
hygien
measur
alcoholbas
hand
gel
use
mask
tissu
cover
mouth
patient
respiratori
ill
survey
us
popul
use
mask
outpati
set
view
accept
mean
reduc
spread
respiratori
infect
hospit
patient
infect
control
recommend
typic
pathogen
specif
detail
use
person
protect
equip
measur
prevent
transmiss
within
health
care
set
refer
healthcar
infect
control
practic
advisori
committe
perform
indic
tool
help
guidelin
user
measur
extent
effect
implement
guidelin
tool
measur
indic
process
outcom
deviat
recommend
expect
proport
case
complianc
case
gener
appropri
depend
indic
four
specif
perform
indic
select
cap
guidelin
focu
treatment
issu
deal
prevent
initi
empir
treatment
cap
consist
guidelin
recommend
data
exist
support
role
cap
guidelin
demonstr
reduct
cost
lo
mortal
guidelin
follow
reason
deviat
guidelin
clearli
document
medic
record
first
treatment
dose
patient
admit
hospit
given
ed
unlik
prior
guidelin
specif
time
frame
recommend
initi
treatment
would
expect
within
h
present
whenev
admiss
diagnosi
like
cap
rush
treatment
without
diagnosi
cap
howev
result
inappropri
use
antibiot
concomit
increas
cost
advers
drug
event
increas
antibiot
select
pressur
possibl
increas
antibiot
resist
consider
given
monitor
number
patient
receiv
empir
antibiot
ed
admit
hospit
without
infecti
diagnosi
mortal
data
patient
cap
admit
ward
icu
highlevel
monitor
unit
collect
although
tool
predict
mortal
sever
ill
psi
criteria
foolproof
overal
mortal
rate
patient
cap
admit
hospit
includ
gener
medic
ward
monitor
compar
severityadjust
norm
addit
care
attent
paid
percentag
patient
sever
cap
defin
document
admit
initi
nonicu
highlevel
monitor
unit
mortal
rate
import
determin
percentag
atrisk
patient
one
practic
actual
receiv
immun
influenza
pneumococc
infect
prevent
infect
clearli
desir
treat
establish
infect
clear
target
group
undervaccin
tri
increas
number
protect
individu
desir
end
point
therefor
goal
worth
pursu
particularli
true
influenza
vaccin
data
compel
import
tri
protect
pneumococc
infect
well
coverag
adult
year
age
target
